[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai Pulmonary Hospital, Shanghai, China\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":643},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,73,0,25,[9,48,80,105,131,152,179,202,223,249,270,289,320,342,364,387,421,448,471,497,525,544,570,590,616],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100616729","impact-of-sugammadex-versus-neostigmine-on-early-postoperative-pulmonary-function-100616729",false,"NCT07309393","Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function","Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function After Thoracoscopic Lung Resection: A Multicenter, Randomized, Double-Blind, Controlled Trial","Inclusion Criteria:\n\n* Scheduled for elective unilateral thoracoscopic partial lung resection, with expected resection not exceeding one lung segment.\n* Age between 18 and 80 years.\n* American Society of Anesthesiologists (ASA) Physical Status classification I-III.\n\nExclusion Criteria:\n\n* Contraindications to drug use, such as history of allergy, epilepsy, angina, ventricular tachycardia; contraindicated in patients with mechanical intestinal obstruction or urinary tract obstruction; contraindicated in cases of arrhythmia, bradycardia (\\\u003C50 beats per minute), hypotension, or increased vagal tone; contraindicated in patients currently using depolarizing muscle relaxants (e.g., succinylcholine).\n* Inability to correctly cooperate with portable lung function testing.\n* Hepatic or renal insufficiency.\n* Pregnancy, lactation, potential for pregnancy, or planning pregnancy.\n* Preoperative history of drug abuse or addiction.\n* Second surgery during postoperative hospitalization.\n* Patients who refuse to participate.\n* Other situations deemed inappropriate by the investigators shall be accompanied by a statement of the reasons.","ALL","18 Years","80 Years",{"count":21,"type":22},240,"ESTIMATED","INTERVENTIONAL",[25],"NA","Residual neuromuscular blockade (NMB) after general anesthesia increases the risk of postoperative respiratory complications (atelectasis, pneumonia, re-intubation) and delays pulmonary function recovery. Sugammadex, a γ-cyclodextrin that directly encapsulates rocuronium, reverses NMB rapidly and completely without cholinergic side effects, whereas neostigmine requires co-administration of an antimuscarinic and may leave residual blockade. In this multicenter, randomized, double-blind, controlled trial, 240 adult patients (ASA I-III) undergoing elective thoracoscopic lung resection (≤ 1 segment) will be randomized 1:1 to receive sugammadex (2 mg\u002Fkg) or neostigmine (0.03 mg\u002Fkg) + atropine (0.015 mg\u002Fkg) at the end of surgery. The primary endpoint is the percent decline in forced expiratory volume in 1 second (FEV₁) at 1 hour post-extubation compared to preoperative baseline; a ≥ 5% improvement with sugammadex is hypothesized. Secondary endpoints include FEV₁ at days 1-3, pain scores, opioid consumption, gastrointestinal recovery, quality of recovery (QoR-15), neuromuscular monitoring (TOF ratio), and incidence of postoperative pulmonary and surgical complications.",[28],"Residual Neuromuscular Block",[30,31,32,33,34],"Sugammadex","Neostigmine","Forced Expiratory Volume (FEV1)","Lung Resection","Quality of Recovery","RECRUITING","2026-06-17",{"date":38,"type":39},"2026-06-22","ACTUAL",{"date":41,"type":39},"2025-12-30",{"date":43,"type":22},"2026-09-30",{"name":45,"class":46},"Shanghai Pulmonary Hospital, Shanghai, China","OTHER",3,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":66,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":4},"100639385","phase-3-neoadjuvant-sf-sbrt-plus-toripalimab-and-chemotherapy-in-resectable-stage-ii-iii-nsclc-100639385","NCT07608159","Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC.","A Randomized, Controlled, Multicenter Phase III Clinical Study of Spatially Fractionated Stereotactic Body Radiotherapy Plus Toripalimab and Chemotherapy Versus Toripalimab Plus Chemotherapy in Patients With Resectable or Potentially Resectable Stage II-III Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n* Male or female participants aged 18 to 75 years;\n* Eastern Cooperative Oncology Group performance status of 0 or 1;\n* Previously untreated, pathologically confirmed, resectable or potentially -resectable stage II, IIIA, or IIIB (N2) non-small cell lung cancer according to the 8th edition of the American Joint Committee on Cancer staging system;\n* At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1;\n* Adequate pulmonary function, as assessed by the surgeon, to tolerate the planned lung resection;\n* Absence of sensitizing EGFR mutations or ALK rearrangements confirmed by tissue-based molecular pathological testing;\n* Adequate organ function, defined as follows:\n\nBone marrow function: absolute neutrophil count ≥1.5 × 10\\^9\u002FL, platelet count ≥80 × 10\\^9\u002FL, and hemoglobin ≥9 g\u002FdL; Liver function: total serum bilirubin ≤1.5 × upper limit of normal; alanine aminotransferase and aspartate aminotransferase ≤1.5 × upper limit of normal; Renal function: serum creatinine ≤1.5 × upper limit of normal or creatinine clearance ≥60 mL\u002Fmin, and blood urea nitrogen ≤200 mg\u002FL;\n\n* Participants must be fully informed about the study and voluntarily sign the written informed consent form.\n* Male participants with reproductive potential or female participants of childbearing potential must agree to use effective contraception during the study, such as oral contraceptives, an intrauterine device, or a barrier method combined with spermicide, and continue contraception for 6 months after completion of treatment.\n\nExclusion Criteria:\n\n* Locally advanced unresectable or metastatic disease. Unresectable disease is defined according to the multidisciplinary consensus for stage III non-small cell lung cancer (2019 edition), including some stage IIIA, stage IIIB, and all stage IIIC disease. This usually includes N2 disease with a single-station mediastinal lymph node with a short-axis diameter ≥3 cm, or multistation lymph node fusion\u002Fconglomeration with lymph nodes having a short-axis diameter ≥2 cm on CT; T4 disease invading the esophagus, heart, aorta, or pulmonary veins; and all N3 disease;\n* Non-small cell lung cancer involving the superior sulcus, large-cell neuroendocrine carcinoma, or sarcomatoid carcinoma;\n* Known sensitizing EGFR mutation or ALK rearrangement. For participants with non-squamous histology, EGFR and ALK mutation status must be confirmed;\n* Prior treatment with PD-1 or PD-L1 inhibitors, or agents targeting another T-cell receptor pathway, such as CTLA-4 or OX-40;\n* Active or suspected active autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, and inflammatory bowel disease. Exceptions include type 1 diabetes mellitus or hypothyroidism controlled with stable replacement therapy, and dermatologic conditions not requiring systemic treatment, such as psoriasis or vitiligo;\n* History of interstitial lung disease of grade 2 or higher;\n* Use of systemic corticosteroids, defined as prednisone \\>10 mg\u002Fday or equivalent, or other immunosuppressive medications within 14 days before the first dose of study treatment;\n* History of immunodeficiency, including acquired or congenital immunodeficiency disorders, history of organ transplantation, or prior allogeneic hematopoietic stem cell transplantation or solid organ transplantation;\n* Receipt of a live vaccine within 4 weeks before the first dose of study treatment;\n* Severe cardiovascular or cerebrovascular disease, including:\n\nPoorly controlled hypertension or pulmonary hypertension;\n\n* Unstable angina, myocardial infarction, coronary artery bypass grafting, or coronary stent implantation within 6 months before study treatment;\n* Chronic heart failure with New York Heart Association class II or higher cardiac function;\n* Left ventricular ejection fraction \\\u003C50%;\n* Severe arrhythmias requiring medical treatment, except atrial fibrillation or paroxysmal supraventricular tachycardia. Examples include QTcF \\>450 msec in males or \\>470 msec in females, complete left bundle branch block, or third-degree atrioventricular block;\n* Cerebrovascular accident or transient ischemic attack within 6 months before study treatment;\n* Uncontrolled or severe underlying medical conditions, including but not limited to active infection requiring systemic antibiotic therapy;\n* Positive human immunodeficiency virus antibody test, active hepatitis B, or active hepatitis C. The following participants may be eligible:\n* Participants positive for hepatitis B core antibody or hepatitis B surface antigen may be enrolled if HBV DNA is below the lower limit of detection at the study site, or \\\u003C500 IU\u002FmL, and active infection is excluded by the investigator based on clinical treatment history and clinical manifestations;\n* Participants positive for hepatitis C antibody may be enrolled if HCV RNA is below the lower limit of detection at the study site;\n* Known active pulmonary tuberculosis. Participants suspected of having active tuberculosis must undergo chest X-ray, sputum examination, and assessment of clinical symptoms and signs to exclude active tuberculosis;\n* History of any active malignancy other than the study disease within 2 years before enrollment, except malignancies expected to be cured after treatment, including but not limited to adequately treated thyroid cancer, carcinoma in situ of the cervix, basal cell or squamous cell skin cancer, or ductal carcinoma in situ of the breast treated with curative surgery;\n* History of psychotropic drug abuse that cannot be discontinued, or history of psychiatric disorder;\n* Pregnant or breastfeeding women;\n* Any other severe, acute, or chronic medical or psychiatric condition, or laboratory abnormality that, in the investigator's judgment, may increase the risk associated with study participation or may interfere with interpretation of the study results.","75 Years",{"count":57,"type":22},201,[59],"PHASE3","This is an open-label, randomized, controlled, multicenter phase III clinical trial designed to evaluate the efficacy and safety of spatially fractionated stereotactic body radiotherapy (SF-SBRT) combined with toripalimab and platinum-based chemotherapy versus toripalimab combined with platinum-based chemotherapy in patients with resectable or potentially resectable stage II-III non-small cell lung cancer (NSCLC). Eligible participants will be randomized 2:1 to receive either neoadjuvant SF-SBRT followed by toripalimab and platinum-based chemotherapy for two cycles, or toripalimab and platinum-based chemotherapy for three cycles. Randomization will be stratified by disease stage and histological subtype. Surgery is planned 4-6 weeks after completion of neoadjuvant treatment, and postoperative adjuvant therapy will be determined by the investigator. The primary endpoint is the 2-year event-free survival rate. Secondary endpoints include pathological complete response rate, major pathological response rate, objective response rate, R0 resection rate, event-free survival, overall survival, and safety. Adverse events will be assessed according to NCI CTCAE version 5.0 or later.",[62,63,64,65],"Non Small Cell Lung Cancer","Stereotactic Body Radiotherapy","Neoadjuvant Chemoimmunotherapy","Surgery",[67,68,69,70],"Spatially fractionated radiotherapy","stereotactic body radiotherapy","non small cell lung cancer","neoadjuvant chemoimmunotherapy","NOT_YET_RECRUITING","2026-05-27",{"date":74,"type":39},"2026-05-29",{"date":76,"type":22},"2026-05",{"date":78,"type":22},"2030-05",{"name":45,"class":46},{"id":81,"slug":82,"hasResults":12,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":12,"sex":17,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":91,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":4},"100639555","oral-paclitaxel-as-neoadjuvant-therapy-in-elderly-nsclc-a-phase-ii-trial-100639555","NCT07599163","Oral Paclitaxel as Neoadjuvant Therapy in Elderly NSCLC: A Phase II Trial","A Phase II, Multicenter Clinical Study of Oral Paclitaxel Solution as Neoadjuvant Therapy in Elderly Patients With Non-Small Cell Lung Cancer","Eligibility Criteria\n\nInclusion Criteria:\n\n* Age 70-85 years, any gender\n* ECOG performance status 0-1\n* Pathologically confirmed non-small cell lung cancer (NSCLC), clinical stage IIA-IIIB (8th edition AJCC)\n* No distant metastasis, deemed resectable with curative intent\n* Negative for sensitive driver mutations including EGFR, ALK, and ROS1 by molecular pathology\n* Adequate function of major organs, defined as:\n* Bone marrow: ANC ≥1.5×10⁹\u002FL, platelet ≥100×10⁹\u002FL, hemoglobin ≥9 g\u002FdL\n* Liver function: total bilirubin ≤1.5×ULN; ALT, AST ≤2.5×ULN\n* Renal function: serum creatinine ≤1.5×ULN or creatinine clearance ≥60 mL\u002Fmin; urine protein \\\u003C +; if +, 24-h urine protein \\\u003C 500 mg\n* Normal blood glucose or well-controlled diabetes\n* Pulmonary function: baseline FEV1 ≥2 L; if FEV1 \\\u003C 2 L, postoperative predicted FEV1 \\> 800 mL confirmed by surgical evaluation\n* Cardiac function: no myocardial infarction, unstable angina, severe arrhythmia, or cardiac insufficiency within the past 1 year\n* Patients and families are fully informed and voluntarily provide written informed consent\n\nExclusion Criteria:\n\n* Previous lobectomy, radiotherapy, or systemic antitumor therapy\n* Synchronous other malignancy with \\\u003C5 years of cure (except carcinoma in situ of the cervix, basal cell or squamous cell carcinoma of the skin)\n* History of active autoimmune disease or requirement for systemic immunosuppressive therapy\n* Active infection requiring systemic therapy, including active tuberculosis, HIV infection, chronic hepatitis B\u002FC with active replication, or syphilis\n* Severe cardiac, hepatic, renal, or metabolic disease that cannot tolerate surgery or study treatment\n* Previous interstitial lung disease, drug-induced pneumonitis, or radiologic evidence of active interstitial lung disease\n* Uncontrolled massive pleural effusion or pericardial effusion\n* Major surgery, severe trauma, or other investigational drug therapy within 4 weeks\n* Recent vaccination with antitumor vaccines or live vaccines\n* Other conditions deemed inappropriate for enrollment or likely to affect trial outcomes by the investigator","70 Years","85 Years",{"count":90,"type":22},75,[25],"This study is a multicenter, single-arm Phase II clinical trial, aiming to explore the safety and preliminary efficacy of oral paclitaxel solution combined with immune checkpoint inhibitors as a neoadjuvant regimen in elderly patients aged 70-85 years with non-small cell lung cancer (NSCLC). A total of 75 eligible elderly NSCLC patients who need neoadjuvant treatment are planned to be enrolled. The study takes Shanghai Pulmonary Hospital as the main center, Zhejiang Cancer Hospital and Guangdong Provincial People's Hospital as sub-centers, adopts a single-arm study design, and the research subjects are elderly NSCLC patients who need neoadjuvant treatment. The core indicators for efficacy evaluation include pathological complete response rate (pCR), major pathological response rate (MPR, residual tumor cells ≤10%), imaging response rate (according to RECIST 1.1 criteria), 2-year event-free survival rate (EFS), 2-year overall survival rate (OS), surgical resection rate, and R0 resection rate; safety evaluation mainly observes the incidence of adverse events. The statistical methods adopt the relevant specifications for single-arm exploratory studies. Efficacy analysis is carried out in the full analysis set and per-protocol set, and safety analysis is performed using the safety analysis set; for continuous variables, paired t-test or Wilcoxon signed-rank test is used according to the distribution; categorical variables are analyzed descriptively; for the main rate-type outcome indicators, the incidence rate and 95% confidence interval (Clopper-Pearson method) are reported; survival outcome indicators are estimated using the Kaplan-Meier method and relevant parameters are reported.",[94,95,96],"Non-Small-Cell Lung Cancer","Neoadjuvant Therapy","Paclitaxel","2026-05-19",{"date":99,"type":39},"2026-05-20",{"date":101,"type":22},"2026-06-08",{"date":103,"type":22},"2030-12-30",{"name":45,"class":46},{"id":106,"slug":107,"hasResults":12,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":114,"briefSummary":115,"conditions":116,"keywords":119,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":126,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},"100637941","application-of-electromagnetic-navigation-system-in-pulmonary-nodule-localization-100637941","NCT07595120","Application of Electromagnetic Navigation System in Pulmonary Nodule Localization","Electromagnetic Navigation-Guided Versus CT-Guided Localization of Pulmonary Nodules: A Multicenter, Prospective, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age 18-80 years, regardless of gender;\n2. Solitary single nodule, scheduled for lung nodule puncture and localization;\n3. Chest CT (lung window mode) showing a maximum nodule diameter ≤ 2 cm;\n4. Eastern Cooperative Oncology Group (ECOG) performance status score 0-2;\n5. Voluntary participation, with signed informed consent.\n\nExclusion Criteria:\n\n1. Not suitable for video-assisted thoracoscopic surgery;\n2. The distance between the center of the lesion and the dome of the diaphragm is \\\u003C 3 cm;\n3. History of thoracic adhesion due to previous thoracotomy or pleural infection;\n4. Patients judged by the investigator to be unsuitable for preoperative transthoracic or transbronchial localization;\n5. Inability to complete follow-up or poor compliance.",{"count":113,"type":22},400,[25],"This study aims to design and conduct a multicenter, prospective, randomized controlled post-market clinical trial to validate the clinical efficacy of high-precision electromagnetic navigation technology.",[117,118],"Pulmonary Nodules","Early-Stage Lung Cancer",[120,121,122,123],"ENB","CT-guided Percutaneous","pulmonary nodules","localization","2026-05-16",{"date":97,"type":39},{"date":76,"type":22},{"date":128,"type":22},"2027-04",{"name":45,"class":46},1,{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":138,"targetDuration":4,"studyType":23,"phases":139,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":130},"100517586","phase-2-neoadjuvant-treatment-for-locally-advanced-thymic-cancer-100517586","NCT06019468","Neoadjuvant Treatment For Locally Advanced Thymic Cancer","Clinical Study of Envolizumab Combined With Radiotherapy for Neoadjuvant Treatment of Locally Advanced Thymic Cancer","Inclusion Criteria:\n\n1. Pathologically confirmed as thymic carcinoma;\n2. Clinical staging III-IVA (TNM staging system), non-myasthenia gravis (MG) patients, expected to undergo surgical resection;\n3. On the day when the subject signs the informed consent form, they are ≥ 18 years old and\\\u003C75 years old, regardless of gender;\n4. The subjects are able to understand the informed consent form, voluntarily participate, and sign the informed consent form;\n5. Subjects who have not received any anti-thymic tumor treatment in the past, including but not limited to systemic chemotherapy, radiotherapy, or immunotherapy (only those who have received traditional Chinese medicine treatment for anti-tumor indications are allowed to be included, and a cleaning period of at least 2 weeks is required);\n6. At least 1 measurable lesion (according to the solid tumor efficacy evaluation standard RECIST V1.1);\n7. Physical fitness score of 0 or 1 (ECOG scoring system of the Eastern Cancer Collaborative Group in the United States);\n8. Female subjects with fertility must have a negative serum pregnancy test within 7 days before the first administration;\n9. Female subjects with fertility or male subjects with partners with fertility agree to use efficient contraceptive measures (with an annual failure rate of less than 1%) from 7 days before the first administration until 24 weeks after the end of administration;\n10. The main organ functions within 7 days before the first administration meet the following standards:\n\n    1. Bone marrow function: hemoglobin ≥ 10.0 g\u002FdL (no blood transfusion received within 28 days before hemoglobin test), absolute neutrophil count ≥ 1.5 × 109\u002FL, platelet count ≥ 100 × 109\u002FL (no platelet transfusion or IL-11 treatment received within 14 days prior to platelet count test);\n    2. Coagulation function: INR and PT\\\u003C1.5 × ULN, APTT ≤ 1.5 × ULN;\n    3. Liver function: transaminases (ALT and AST) ≤ 2.5 × ULN; Total bilirubin ≤ 1.5 × ULN (total bilirubin ≤ 2.5 in subjects with Gilbert's syndrome or liver metastasis) × ULN);\n    4. Renal function: serum creatinine clearance rate ≥ 60 mL\u002Fmin (calculated according to Cockcroft Fault formula);\n    5. Adequate lung function: According to the doctor's judgment, lung function can meet the requirements of thymectomy surgery.\n\nExclusion Criteria:\n\n1. Pathologically confirmed as a thymic neuroendocrine tumor;\n2. Subjects who have undergone major surgical treatment (such as abdominal or thoracic surgery; excluding diagnostic puncture or peripheral vascular pathway replacement surgery) or have not recovered from surgical treatment within 28 days before the administration of this trial;\n3. Within 14 days before the first administration of this study, systemic corticosteroids (≥ 10 mg\u002Fday prednisone, or equivalent amounts of other corticosteroids) or immunosuppressive therapy are required for 7 consecutive days; Excluding inhalation or local application of hormones, or receiving physiological replacement doses of hormone therapy due to adrenal insufficiency; Allow short-term (\\\u003C7 days) use of corticosteroids for prevention (such as contrast agent allergies) or treatment of non-autoimmune diseases (such as delayed hypersensitivity reactions caused by exposure to allergens);\n4. Received live vaccines (including attenuated live vaccines) within 28 days prior to administration in this study;\n5. Previously or currently suffering from interstitial pneumonia\u002Flung disease that requires systemic hormone therapy;\n6. Previously or currently suffering from autoimmune diseases, including but not limited to Crohn's disease, ulcerative colitis, systemic lupus erythematosus, sarcoidosis, Wegener syndrome (granulomatosis of vasculitis, Graves disease, rheumatoid arthritis, pituitary inflammation, uveitis), autoimmune hepatitis, systemic sclerosis (scleroderma, etc.), Hashimoto's thyroiditis (exceptions see below), autoimmune vasculitis Autoimmune neuropathy (Guillain Barre syndrome), etc. The following cases are excluded: type I diabetes, hypothyroidism with stable hormone replacement therapy (including hypothyroidism caused by autoimmune thyroid disease), psoriasis or vitiligo without systemic treatment;\n7. Other malignant tumors were combined within 5 years before the first administration, excluding cured skin squamous cell carcinoma, basal cell carcinoma, non-muscle invasive bladder cancer, localized low-risk prostate (defined as stage ≤ T2a, Gleason score ≤ 6, and PSA ≤ 10ng\u002FmL at the time of diagnosis of prostate cancer (if measured, patients who have received radical treatment and have no PSA biochemical relapse can participate in this study), and in situ cervical\u002Fbreast cancer;\n8. Have uncontrolled heart, kidney, gastrointestinal tract, infectious diseases and other complications;\n9. Previous history of allogeneic bone marrow or organ transplantation;;\n10. Previously treated with any antibody\u002Fdrug (immune checkpoint) targeting T cell co-regulatory proteins, such as anti PD (L) 1, CTLA-4, 4-1BB, LAG 3, TIM 3, or anti CD127; Previously received anti-tumor vaccine treatment\n11. Previous history of allergic reactions to antibody-based drugs and intolerance (≥ Level 3 NCI-CTCAE V5.0); Any past history of rapid allergic reactions and uncontrollable asthma (i.e. uncontrollable asthma symptoms of 3 or more of the 3 or more characteristics of partially controlled asthma); Previous obvious allergies to drugs (such as severe allergic reactions, immune-mediated hepatotoxicity, immune-mediated thrombocytopenia or anemia);\n12. Pregnant and\u002For lactating women;\n13. Other situations that may affect the safety or compliance of drug treatment in this study, including but not limited to mental illness, uncontrolled large amounts of serous fluid accumulation, or subjects who require repeated drainage (recurrence within 2 weeks after intervention) with moderate to large amounts of serous fluid accumulation, cachexia, etc.",{"count":7,"type":22},[140],"PHASE2","The aims of this study are to verify the feasibility, effectiveness, and safety of the combination of enrolizumab and radiotherapy for neoadjuvant treatment for locally advanced thymic carcinoma, and to provide recommendations for the establishment of unified evaluation criteria for the neoadjuvant therapy of thymic cancer by evaluating the pathological remission status of thymic cancer specimens after neoadjuvant treatment.",[143],"Thymic Carcinoma","2026-05-05",{"date":146,"type":39},"2026-05-08",{"date":148,"type":39},"2023-11-04",{"date":150,"type":22},"2026-12-30",{"name":45,"class":46},{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":159,"targetDuration":4,"studyType":23,"phases":161,"briefSummary":162,"conditions":163,"keywords":166,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":4},"100635026","phase-2-nab-paclitaxel-combined-with-local-therapy-in-relapsed-sclc-100635026","NCT07547332","Nab-Paclitaxel Combined With Local Therapy in Relapsed SCLC","A Single-arm, Multicenter, Exploratory Study to Evaluate the Efficacy and Safety of Nab-paclitaxel Combined With Local Therapy in Patients With Small-cell Lung Cancer Receiving Second-line or Subsequent Treatment","Inclusion Criteria:\n\n* (1) Written informed consent has been signed. (2) Male or female, aged 18-75 years. (3) Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n\n  (4) Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC) according to the Veterans Administration Lung Group (VALG) staging system.\n\n  (5) Patients with ES-SCLC who have received at least one prior line of systemic therapy.\n\n  (6) Patients with previously treated asymptomatic central nervous system (CNS) metastases are eligible if all of the following criteria are met:\n  * Only supratentorial and cerebellar metastases (i.e., no metastases in the midbrain, pons, medulla oblongata, or spinal cord);\n\n    * No requirement for ongoing corticosteroid therapy for CNS disease;\n\n      * No stereotactic radiotherapy within 7 days prior to randomization;\n\n        * No disease progression observed on imaging from completion of CNS-directed therapy through screening;\n\n          ⑤ If new asymptomatic CNS metastases are detected on screening imaging, patients must receive radiotherapy and\u002For resection of CNS lesions. After such treatment, these patients may be randomized without additional brain scans if all other eligibility criteria are satisfied.\n\n          (7) Presence of measurable disease as defined by RECIST v1.1. A previously irradiated lesion may be considered measurable only if clear disease progression has occurred after radiotherapy and the lesion is not the only site of disease.\n\n          (8) Adequate hematologic and end-organ function as defined by laboratory results obtained within 14 days prior to randomization:\n  * Absolute neutrophil count (ANC) ≥ 1500 cells\u002FμL without granulocyte colony-stimulating factor support; lymphocyte count ≥ 500 cells\u002FμL;\n\n    * Platelet count ≥ 100,000\u002FμL without transfusion; hemoglobin ≥ 9.0 g\u002FdL (may be achieved by transfusion); ③ International normalized ratio (INR) or activated partial thromboplastin time (aPTT) ≤ 1.5 × upper limit of normal (ULN). This criterion applies only to patients not receiving anticoagulation. Patients on anticoagulation must be on a stable dose; ④ Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase ≤ 2.5 × ULN, except: Patients with confirmed liver metastases: AST and\u002For ALT ≤ 5 × ULN; Patients with confirmed liver or bone metastases: alkaline phosphatase ≤ 5 × ULN;\n\n      * Serum bilirubin ≤ 1.25 × ULN. For patients with known Gilbert's disease, serum bilirubin ≤ 3 × ULN is permitted;\n\n        * Serum creatinine ≤ 1.5 × ULN. (9) Patients must provide a pre-treatment tumor tissue sample during the study. Any available tumor tissue sample is acceptable. Submission may be completed after enrollment.\n\nExclusion Criteria:\n\n* Patients meeting any of the following criteria are ineligible:\n\nActive or untreated CNS metastases detected by computed tomography (CT) or magnetic resonance imaging (MRI) during screening or on prior imaging.\n\nSpinal cord compression not radically treated with surgery and\u002For radiotherapy, or previously diagnosed spinal cord compression without clinical evidence of stable disease for at least 1 week prior to randomization.\n\nLeptomeningeal metastases. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage (once per month or more frequently); indwelling catheters are not permitted.\n\nUncontrolled or symptomatic hypercalcemia (\\> 1.5 mmol\u002FL ionized calcium, serum calcium \\> 12 mg\u002FdL, or corrected serum calcium \\> ULN).\n\nHistory of malignancy other than SCLC within 5 years prior to randomization, except for malignancies with negligible risk of metastasis or death (e.g., 5-year OS \\> 90%) and curative potential after treatment, such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer with radical surgery, or ductal carcinoma in situ with radical surgery.\n\nPregnant or lactating women, or women planning pregnancy during the study period.\n\nHistory of severe allergic, hypersensitivity, or anaphylactic reactions to chimeric, humanized, or human antibodies or fusion proteins.\n\nKnown hypersensitivity to any component of biologic medicinal products produced in Chinese hamster ovary (CHO) cells or to the study drug formulation.\n\nHistory of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, and glomerulonephritis.\n\nPatients with a history of autoimmune hypothyroidism on a stable dose of thyroid hormone replacement therapy are eligible.\n\nPatients with type 1 diabetes mellitus controlled on a stable insulin regimen are eligible.\n\nPatients with eczema, psoriasis, lichen simplex chronicus, or vitiligo only (patients with psoriatic arthritis are excluded) may be enrolled if:\n\n* Rash involves \\\u003C 10% of body surface area; ② Disease is well controlled at baseline requiring only low-potency topical corticosteroids; ③ No acute exacerbation of underlying disease in the past 12 months (no requirement for PUVA, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, high-potency or oral corticosteroids).\n\nHistory of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonia, or active pneumonitis on screening chest CT scan.\n\nSevere interstitial lung disease. Positive human immunodeficiency virus (HIV) test. Active hepatitis B (chronic or acute; defined as positive hepatitis B surface antigen \\[HBsAg\\] at screening) or hepatitis C virus (HCV) infection.\n\nPatients with resolved or prior HBV infection (positive hepatitis B core antibody \\[HBcAb\\] and negative HBsAg) are eligible. HBV DNA testing must be performed prior to randomization.\n\nAmong patients positive for HCV antibody, only those with negative HCV RNA by PCR are eligible.\n\nActive tuberculosis. Severe infection at enrollment, including but not limited to infectious complications requiring hospitalization, bacteremia, severe pneumonia, etc.\n\nSevere cardiovascular disease, such as New York Heart Association (NYHA) Class II or higher heart failure, myocardial infarction within 3 months prior to randomization, unstable arrhythmia, or unstable angina.\n\nPatients with known coronary artery disease, congestive heart failure not meeting the above criteria, or left ventricular ejection fraction \\\u003C 50% must be on optimal stable therapy as judged by the treating physician, with cardiology consultation if necessary.\n\nMajor surgery within 28 days prior to randomization (except diagnostic surgery) or expected major surgery during the study.\n\nHistory of allogeneic bone marrow transplantation or solid organ transplantation.\n\nAny other disease, metabolic dysfunction, physical finding, or laboratory abnormality that, in the investigator's judgment, would contraindicate use of the study drug, interfere with interpretation of study results, or place the patient at high risk of treatment-related complications.\n\nPrior receipt of anti-tumor therapy for ES-SCLC. Treatment with any other investigational agent or participation in another therapeutic clinical trial within 28 days prior to randomization.\n\nLive attenuated vaccine within 4 weeks prior to randomization or anticipated need for such vaccines during the study.\n\nPrior treatment with CD137 agonists, immune checkpoint blockade therapy, anti-PD-1, or anti-PD-L1 therapeutic antibodies.\n\nSystemic immunosuppressive therapy within 2 weeks prior to randomization, including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor (anti-TNF) agents.\n\nPatients receiving short-term, low-dose systemic immunosuppression (e.g., single-dose dexamethasone for nausea) may be eligible after discussion and approval by the investigator and medical monitor.\n\nUse of inhaled corticosteroids for chronic obstructive pulmonary disease, mineralocorticoids (e.g., fludrocortisone) for orthostatic hypotension, and low-dose corticosteroid replacement for adrenal insufficiency is permitted.\n\nHistory of hypersensitivity to platinum agents or etoposide.",{"count":160,"type":22},84,[140],"This is a prospective, single-arm, investigator-initiated clinical study (IIT) designed to evaluate the efficacy and safety of nab-paclitaxel combined with local radiotherapy for patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed after first-line treatment.\n\nSmall cell lung cancer (SCLC) is an aggressive type of lung cancer, and extensive-stage SCLC (ES-SCLC) refers to its advanced stage. For patients whose cancer progresses after first-line treatment, there are very limited effective second-line and later-line treatment options. Commonly used clinical regimens such as topotecan and lurbinectedin only provide modest improvements in tumor response and survival, and often cause severe hematological toxicities (represented by bone marrow suppression). This leaves patients in a persistent dilemma of \"insufficient efficacy and limited tolerability\", highlighting a clear unmet medical need for better treatment options in this population.\n\nAgainst this background, this study explores a comprehensive treatment strategy using nab-paclitaxel as the chemotherapy backbone, combined with local radiotherapy in eligible patients. Nab-paclitaxel is a nanoparticle albumin-bound form of paclitaxel, with a relatively controllable toxicity profile and manageable administration in clinical practice. Local radiotherapy may create a synergistic effect by improving the tumor immune microenvironment and enhancing local tumor control, with the goal of providing better evidence for a \"chemotherapy ± local therapy\" combination as a second-line treatment option.",[164,165],"Small Cell Lung Cancer","Extensive Stage Small Cell Lung Cancer (ES-SCLC)",[167,168,169,170],"small cell lung cancer","sclc","extensive stage small cell lung cancer","es-sclc","2026-04-20",{"date":173,"type":39},"2026-04-23",{"date":175,"type":22},"2026-04-06",{"date":177,"type":22},"2030-12-31",{"name":45,"class":46},{"id":180,"slug":181,"hasResults":12,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":12,"sex":17,"minAge":186,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":23,"phases":190,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":201},"100434450","segmentectomy-versus-lobectomy-for-lung-adenocarcinoma--2cm-100434450","NCT04937283","Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm","Comparison of Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm With Micropapillary and Solid Subtype Negative by Intraoperative Frozen Sections: A Prospective and Multi-center Randomized Controlled Trial Study","Inclusion Criteria:\n\n* Patient aged 20-79 years old, both male or female;\n* Tumor size \\\u003C= 2cm on preoperative CT scan;\n* Peripheral solitary nodule or the associated lesion is MIA or less invasive lesion;\n* Preoperative CT indicated that the nodules were non-pure glass nodules (consolidation to tumor ratio \\>= 0.25);\n* Intraoperative frozen section confirmed invasive lung adenocarcinoma with micropapillary and solid subtype negative (\\\u003C= 5%);\n* Intraoperative frozen section indicated the resection margins was free of tumor cells;\n* Lung function could withstand both lung segmentectomy and lobectomy (FEV1 \\> 1.5L or FEV1% \\>= 60%);\n* Eastern Cooperative Oncology Group, 0 to 2;\n* Volunteer to participate the trial and sign the informed consent, able to comply with the follow-up plan and other program requirements.\n\nExclusion Criteria:\n\n* Radiological pure ground glass nodules (consolidation to tumor ratio \\\u003C 0.25);\n* The nodule is close to the lung hilus and is unable to perform segmentectomy;\n* Intraoperative frozen section confirmed with micropapillary and solid subtype positive (\\> 5%);\n* Intraoperative frozen section confirmed adenocarcinoma in situ and minimally invasive adenocarcinoma;\n* Preoperative imaging examination or EBUS indicated lymph node positive metastasis;\n* Preoperative imaging examination revealed distant metastasis;\n* Patients with severe damage to heart, liver and kidney function (grade 3 \\~ 4, ALT and\u002For AST over 3 times the normal upper limit, Cr over the normal upper limit);\n* Patients with other malignant tumors;\n* Pregnant, planned pregnancy and lactating female patients (urine HCG\\>2500IU\u002FL is diagnosed as early pregnancy);\n* Prior chemotherapy, radiation therapy or any other therapies were performed; 12 participated in other tumors within three months of relevant clinical subjects;\n* Those who have participated in other tumor-related clinical trials within three months;\n* Those are not suitable for participating in trials according to investigator's assessment.","20 Years","79 Years",{"count":189,"type":22},690,[25],"This study aims to evaluate the non-inferiority in recurrence-free survival and overall survival of segmentectomy compared with lobectomy in patients with lung adenocarcinoma ≤ 2 cm with micropapillary and solid subtype negative by intraoperative frozen sections.",[193],"Lung Adenocarcinoma",{"date":195,"type":39},"2026-04-13",{"date":197,"type":39},"2019-10-01",{"date":199,"type":22},"2028-12-30",{"name":45,"class":46},14,{"id":203,"slug":204,"hasResults":12,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":23,"phases":211,"briefSummary":212,"conditions":213,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":130},"100632742","phase-2-combining-furmonertinib-with-local-therapy-for-inoperable-early-stage-lung-cancer-a-phase-ii-trial-100632742","NCT07517640","Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial","Furmonertinib Combined With Local Therapy in Inoperable or Surgery-Refusing Early-Stage Non-Small Cell Lung Cancer:A Single-arm, Phase II Study","Inclusion Criteria:\n\n* Voluntarily participate in the clinical study\n* Aged ≥ 18 years at the time of signing the informed consent form\n* Histologically or cytologically confirmed early-stage T1-3 N0 NSCLC, or patients with multiple primary lesions or solitary pulmonary parenchymal recurrence\n* Confirmed presence of EGFR-sensitive mutations by genetic testing, including but not limited to Exon 19 deletion, L858R, G719X, L861Q, S768I, and their compound mutations\n* ECOG performance status score of 0-2\n* Deemed medically inoperable or refuse surgery after multidisciplinary evaluation\n* Pulmonary lesions suitable for ablation or radiotherapy (either modality)\n* Adequate major organ function\n\nExclusion Criteria:\n\n* Known severe allergic reaction (NCI-CTCAE v5.0 grade ≥ 3) to any monoclonal antibody or any excipient of the study drug\n* Known contraindications to ablation or radiotherapy\n* Failure to meet the minimum requirements for target coverage and dose constraints to organs at risk in the SABR treatment plan\n* Active infection requiring systemic anti-infective therapy within 14 days prior to the first dose\n* Patients with hepatitis B (hepatitis B surface antigen \\[HBsAg\\] positive and detectable HBV-DNA indicating viral replication); hepatitis C (hepatitis C virus \\[HCV\\] antibody positive and detectable HCV-RNA indicating viral replication)\n* Receipt of curative-intent radiotherapy within 3 months prior to the first dose\n* Major surgery within 28 days prior to the first dose (major surgery in this study is defined as any procedure requiring at least 3 weeks of recovery before the study treatment can be administered)\n* Concurrent participation in another clinical study, or receipt of intervention in any other clinical trial (including drugs and devices) within 3 months or 5 half-lives prior to screening, whichever is longer\n* Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in this study",{"count":210,"type":22},45,[140],"The goal of this Single-arm, Phase II clinical trial is to learn whether ablation or stereotactic radiotherapy combined with furmonertinib can treat early-stage non-small cell lung cancer in patients who are inoperable or refuse surgery.\n\nThe main purposes of this study is to answer:\n\nCan ablation or stereotactic radiotherapy combined with furmonertinib improve survival in patients with early-stage NSCLC who are inoperable or refuse surgery? Can ablation or stereotactic radiotherapy combined with furmonertinib reduce recurrence in patients with early-stage NSCLC who are inoperable or refuse surgery?",[214],"Non-small Cell Lung Cancer","2026-03-31",{"date":217,"type":39},"2026-04-08",{"date":219,"type":22},"2026-04-01",{"date":221,"type":22},"2028-08-31",{"name":45,"class":46},{"id":224,"slug":225,"hasResults":12,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":230,"targetDuration":4,"studyType":23,"phases":232,"briefSummary":233,"conditions":234,"keywords":237,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":130},"100603295","thoracic-surgery-intercostal-block-trial-with-liposomal-vs-hydrochloride-bupivacaine-100603295","NCT07134660","Thoracic Surgery Intercostal Block Trial With Liposomal vs. Hydrochloride Bupivacaine","Analgesic Efficacy Between Liposomal Bupivacaine and Bupivacaine Hydrochloride in Intercostal Nerve Block for Thoracic Surgery: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Scheduled for elective unilateral thoracoscopic (VATS) lung surgery\n* Age 18 to 80 years\n* American Society of Anesthesiologists (ASA) physical status I-III\n\nExclusion Criteria:\n\n* Contraindication to local anesthetics (infection at puncture site, allergy to local anesthetics, coagulopathy or other bleeding risk)\n* Sensory abnormalities in the planned chest-wall surgical area\n* Hepatic dysfunction (ALT \\> 50 U\u002FL, AST \\> 40 U\u002FL, or total bilirubin ≥ 19 μmol\u002FL) or renal dysfunction (serum creatinine \\> 112 μmol\u002FL, BUN \\> 7.1 mmol\u002FL, or dialysis within 28 days before surgery)\n* Pregnancy, breastfeeding, women of childbearing potential not using adequate contraception, or planning pregnancy during the study period\n* Preoperative opioid use, history of chronic pain, or history of opioid abuse\n* Refusal to provide informed consent",{"count":231,"type":22},210,[25],"This randomized controlled trial evaluates the analgesic effects of liposomal bupivacaine compared to bupivacaine hydrochloride in intercostal nerve block for patients undergoing thoracoscopic lung surgery. Postoperative pain remains a significant issue in thoracic procedures, often leading to complications like pneumonia or delayed recovery. The investigators hypothesize that liposomal bupivacaine, with its extended-release properties, will provide superior pain relief beyond 24 hours compared to standard bupivacaine or no block. Participants will be randomized 1:1:1 to liposomal bupivacaine group , bupivacaine hydrochloride group , or control group . Primary outcome is the area under the curve of pain scores from 25-72 hours post-surgery. Secondary outcomes include opioid consumption, recovery quality (QoR-15), and other complications.",[235,236],"Postoperative Pain, Acute","Lung Cancer",[238,239,240],"Postoperative Pain","Intercostal Nerve Block","Liposomal Bupivacaine","2026-03-25",{"date":243,"type":39},"2026-03-30",{"date":245,"type":39},"2025-09-01",{"date":247,"type":22},"2026-09-20",{"name":45,"class":46},{"id":250,"slug":251,"hasResults":12,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":256,"targetDuration":4,"studyType":23,"phases":258,"briefSummary":259,"conditions":260,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":130},"100630923","phase-2-study-on-the-efficacy-and-safety-of-jskn016-as-neoadjuvant-therapy-in-resectable-stage-ii-iii-non-small-cell-lung-cancer-patients-100630923","NCT07493980","Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients","Study on the Efficacy and Safety of JSKN016 Combined With Toripalimab and Carboplatin as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients","Inclusion Criteria:\n\n* The subject is able to understand the informed consent form, voluntarily participate in the study, and has signed the informed consent form.\n* The subject is ≥18 years and ≤80 years of age on the day of signing the informed consent form; both males and females are eligible.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Histologically or cytologically confirmed resectable stage II, IIIA, or IIIB non-small cell lung cancer (NSCLC), according to the AJCC 9th edition TNM staging system for lung cancer.\n* The subject has not previously received any anti-tumor therapy, including but not limited to systemic chemotherapy, immunotherapy, targeted therapy, or radiotherapy. Subjects who have received traditional Chinese medicine for anti-tumor indications are permitted to enroll provided a washout period of at least 2 weeks has elapsed.\n* Tumor tissue genetic testing confirms NSCLC without EGFR sensitizing mutations (19del\u002FL858R) and negative for ALK fusion genes.\n\nNote: EGFR status may be determined using cytological or blood-based testing results. For subjects with squamous NSCLC, if EGFR and ALK status are previously unknown, testing is not required prior to enrollment in this study and will be considered negative.\n\n* At least one measurable lesion at baseline according to RECIST version 1.1.\n* Adequate organ function. The following laboratory test results must be obtained within 7 days prior to the first dose (echocardiography is permitted within 28 days prior to the first dose):\n\n  1. Bone marrow function (no transfusion of whole blood or blood components within 14 days before the first dose; no hematopoietic growth factors within 7 days before the first dose):\n\n     Absolute neutrophil count ≥ 1.5 × 10⁹\u002FL Hemoglobin ≥ 90 g\u002FL Platelet count ≥ 100 × 10⁹\u002FL\n  2. Liver function:\n\n     Total bilirubin ≤ 1.5 × upper limit of normal (ULN) ALT and AST ≤ 3 × ULN\n  3. Renal function:\n\n     Serum creatinine ≤ 1.5 × ULN, or creatinine clearance (Ccr) ≥ 50 mL\u002Fmin calculated using the Cockcroft-Gault formula (see Appendix 4)\n  4. Coagulation function:\n\n     International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN\n  5. Cardiac function:\n\n     Left ventricular ejection fraction (LVEF) ≥ 50% measured by echocardiography\n  6. Pulmonary function:\n\nPulmonary function considered adequate for surgery as determined by the investigator.\n\n* Female subjects of childbearing potential or male subjects whose partners are of childbearing potential must agree to use highly effective contraception from the time of signing the informed consent form until 24 weeks after the last dose. Female subjects of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to the first dose.\n* The subject is able and willing to comply with study protocol requirements, including study visits, treatment plans, laboratory tests, and other study-related procedures.\n\nExclusion Criteria:\n\n* Histopathological evidence of any small cell carcinoma component, or diagnosis of large cell neuroendocrine carcinoma or sarcomatoid carcinoma.\n* Presence of another malignancy within 3 years prior to the first dose, except for tumors that have been clinically cured by local treatment and have an extremely low risk of recurrence (e.g., cutaneous squamous cell carcinoma, basal cell carcinoma of the skin, non-muscle-invasive bladder cancer, carcinoma in situ of the cervix, localized prostate cancer, etc.), or tumors with disease-free survival ≥ 3 years after curative treatment and an extremely low risk of recurrence or metastasis (e.g., ductal carcinoma in situ after radical surgery, papillary thyroid carcinoma after radical surgery, etc.).\n* Insufficient washout from prior treatments before the first dose, including:\n\n  1. Use of any investigational drug within 28 days prior to the first dose;\n  2. Use of traditional Chinese herbal medicine or proprietary Chinese medicine with clear anti-tumor indications within 14 days prior to the first dose;\n  3. Receipt of non-specific immunomodulatory therapy (e.g., interleukin, interferon, thymosin, tumor necrosis factor, etc.) within 14 days prior to the first dose;\n  4. Requirement for systemic glucocorticoids (\\>10 mg\u002Fday prednisone or equivalent doses of other glucocorticoids) for more than 7 consecutive days, or immunosuppressive therapy, within 14 days prior to the first dose.\n\n     Exceptions include inhaled or topical corticosteroids, or physiologic replacement doses for adrenal insufficiency. Short-term (≤7 days) corticosteroid use is permitted for prophylaxis (e.g., prevention of contrast-agent allergy) or treatment of non-autoimmune conditions (e.g., delayed hypersensitivity due to allergen exposure);\n  5. Major surgery (e.g., abdominal or thoracic surgery) within 28 days prior to the first dose, excluding minor procedures such as diagnostic puncture, implantation of infusion devices, or biliary stent placement, or anticipated need for major surgery during the study period;\n  6. Receipt of live vaccines within 28 days prior to the first dose, or planned administration of live vaccines during the study period.\n* Presence of interstitial lung disease (ILD) or risk factors related to non-infectious pneumonitis, including:\n\n  1. History or current presence of ILD or non-infectious pneumonitis requiring systemic glucocorticoids or other immunosuppressive therapy;\n  2. Suspected ILD or non-infectious pneumonitis that cannot be excluded by imaging during the screening period.\n* Presence of active autoimmune disease requiring systemic treatment within the past 2 years (e.g., treatment with disease-modifying agents, corticosteroids, or immunosuppressive drugs).\n\nNote: Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered systemic treatment.\n\n* Uncontrolled infections, including but not limited to:\n\n  1. Active HBV or HCV infection. Patients positive for HBsAg must undergo HBV-DNA testing; if HBV-DNA exceeds the lower limit of detection of the local laboratory, enrollment is permitted provided antiviral therapy is administered.\n\n     Patients positive for HCV-Ab may be enrolled if HCV-RNA is negative;\n  2. Severe infection within 4 weeks prior to the first dose, including but not limited to infections with complications requiring hospitalization, sepsis, or severe pneumonia; or active infection requiring systemic anti-infective therapy within 2 weeks prior to the first dose;\n  3. History of immunodeficiency, positive HIV test, or history of acquired immunodeficiency syndrome (AIDS);\n  4. Known active tuberculosis;\n  5. Active syphilis.\n* History of allogeneic bone marrow transplantation or organ transplantation.\n* Known hypersensitivity to any component of the investigational drug, or a history of severe allergic reactions to other antibody-based therapies.\n* Pregnant or breastfeeding women, or women planning to become pregnant during the study period.\n* Known psychiatric disorders, substance abuse, alcohol abuse, or any other condition that, in the investigator's judgment, may affect the safety of study treatment or subject compliance.\n* Any other disease, treatment, or laboratory abnormality, either past or present, that in the investigator's judgment may interfere with the evaluation of safety or efficacy, prevent full participation in the study, or make participation not in the subject's best interest.",{"count":257,"type":22},54,[140],"This study aims to evaluate the efficacy and safety of JSKN016 combined with toripalimab and carboplatin as a neoadjuvant treatment regimen in patients with resectable stage II-III NSCLC.",[261],"NSCLC Stage II","2026-03-20",{"date":264,"type":39},"2026-03-27",{"date":266,"type":22},"2026-03",{"date":268,"type":22},"2029-01-01",{"name":45,"class":46},{"id":271,"slug":272,"hasResults":12,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":277,"enrollmentInfo":278,"targetDuration":4,"studyType":23,"phases":280,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":285,"startDateStruct":286,"completionDateStruct":287,"leadSponsor":288,"locationsCount":47},"100630970","teas-for-ipsilateral-shoulder-pain-after-video-assisted-thoracoscopic-lung-surgery-100630970","NCT07494591","TEAS for Ipsilateral Shoulder Pain After Video-Assisted Thoracoscopic Lung Surgery","Preoperative Transcutaneous Electrical Acupoint Stimulation for Ipsilateral Shoulder Pain After Video-Assisted Thoracoscopic Lung Surgery: A Multi-Center, Single-Blind, Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients scheduled for unilateral thoracic surgery\n* Age ≥ 18 years, regardless of gender\n* ASA physical status classification I-III\n* No severe cardiopulmonary insufficiency or other major comorbidities\n\nExclusion Criteria:\n\n* Pre-existing shoulder pain or functional impairment\n* Severe mental illness or cognitive impairment\n* Bilateral thoracic surgery\n* Any other conditions deemed inappropriate by the investigators (with reasons to be documented)","99 Years",{"count":279,"type":22},216,[25],"Shoulder pain is a common problem after certain types of lung surgery called video-assisted thoracoscopic surgery (VATS). This study examines whether a treatment called transcutaneous electrical acupoint stimulation (TEAS) can help reduce this pain. TEAS is a non-invasive technique that uses mild electrical stimulation at specific points on the body.Patients who are having VATS lung surgery will be randomly assigned to either receive TEAS before surgery or standard care. Researchers will measure how much shoulder pain patients experience and compare the two groups.The goal is to see if TEAS can help patients feel less pain and recover better after this type of lung surgery.",[283,284],"Ipsilateral Shoulder Pain","Video-Assisted Thoracoscopic Surgery",{"date":264,"type":39},{"date":219,"type":22},{"date":150,"type":22},{"name":45,"class":46},{"id":290,"slug":291,"hasResults":12,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":295,"eligibilityCriteria":296,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":23,"phases":299,"briefSummary":301,"conditions":302,"keywords":307,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":130},"100629041","phase-4-a-clinical-trial-on-the-outcomes-of-comprehensive-enhanced-prophylaxis-management-cepm-in-chinese-patients-with-egfr-mutated-advanced-nsclc-receiving-amivantamab-based-regimens-100629041","NCT07469488","A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens","AmiCARE: A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens","AmiCARE","Inclusion Criteria:\n\n* Aged at least 18 (or the legal age of consent in the jurisdiction in which the study is taking place) at the time of informed consent.\n* Participants have a confirmed diagnosis of locally advanced or metastatic EGFR-mutated NSCLC (Stage IIIB\u002FC or IV).\n* Participant \\[and\u002For their legally authorized representative where applicable\\] must sign an ICF allowing source data verification in accordance with local requirements and indicating that the participant understands the purpose of and procedures required for the study and is willing to participate in the study.\n* Participants have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1.\n* Participants with asymptomatic or previously treated and stable brain metastases may participate in this study. Participants who have completed definitive therapy, are not on steroids, and have a stable clinical status for at least 2 weeks prior to study treatment are allowed.\n* Be eligible for, and agree to comply with, the use of enhanced dermatologic management and enhanced IRR prophylaxis management during the duration of anticancer treatments with amivantamab and lazertinib, or amivantamab with chemotherapy.\n\nCohort 1 (cEGFR 1L):\n\n* EGFR mutation must be an Ex19del or Ex21 L858R substitution.\n* Participants who plan to receive Amivantamab (IV form) and Lazertinib regimen treatment based on physician's medical judgement.\n* Participant is treatment-naive and not amenable to curative therapy including surgical resection or (chemo)radiation. Adjuvant or neoadjuvant therapy is allowed if last dose administered more than 12 months prior to the development of locally advanced or metastatic disease.\n* Be eligible for, and agree to comply with, the use of prophylactic-dose anticoagulation with a direct oral anticoagulant or a low molecular weight heparin during the first 4 months of anticancer treatment (from Day 1-120) according to Chinese Society of Clinical Oncology (CSCO) guidelines.\n\nCohort 2 (cEGFR 2L):\n\n* EGFR mutation must be an Ex19del or Ex21 L858R substitution.\n* Participants who plan to receive Amivantamab (IV form) and Chemotherapy regimen treatment based on physician's medical judgement.\n* Participants must have progressed on or after prior therapy including an EGFR TKI for advanced or metastatic NSCLC. Amivantamab and chemotherapy will be received as a second-line treatment.\n\nCohort 3 (EGFR Ex20ins 1L):\n\n* EGFR mutation must be an EGFR Ex20ins.\n* Participants who plan to receive Amivantamab (IV form) and Chemotherapy regimen treatment based on physician's medical judgement.\n* Participant is treatment-naive and not amenable to curative therapy including surgical resection or (chemo)radiation. Adjuvant or neoadjuvant therapy for is allowed if last dose administered more than 12 months prior to the development of locally advanced or metastatic disease.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding.\n* Is currently enrolled in an interventional clinical study.\n* Any condition for which, at the investigator's discretion, participation would not be in the best interest of the participant (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.",{"count":298,"type":22},122,[300],"PHASE4","This study aims to explore the clinical outcomes of Comprehensive Enhanced Preventive Management (CEPM) combined with an amivantamab-containing treatment regimen in Chinese patients with EGFR-mutated advanced NSCLC.",[303,304,305,306],"NSCLC (Advanced Non-small Cell Lung Cancer)","VTE (Venous Thromboembolism)","Rash Due to Epidermal Growth Factor Receptor Inhibitors","Infusion Reaction",[308,309,310,311],"Amivantamab","Lazertinib","NSCLC","EGFR","2026-03-09",{"date":314,"type":39},"2026-03-13",{"date":316,"type":22},"2026-04-30",{"date":318,"type":22},"2029-12-31",{"name":45,"class":46},{"id":321,"slug":322,"hasResults":12,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":4,"eligibilityCriteria":326,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":327,"targetDuration":4,"studyType":23,"phases":329,"briefSummary":330,"conditions":331,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":130},"100624361","phase-2-ibi363-pd-1il-2-bias-in-combination-with-chemotherapy-as-neoadjuvant-therapy-in-initially-unresectable-stage-iii-non-small-cell-lung-cancer-100624361","NCT07408635","IBI363 (PD-1\u002FIL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer","IBI363 (PD-1\u002FIL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy to Convert Initially Unresectable Stage III Non-Small Cell Lung Cancer To Resectable Disease: a Phase II, Single-Arm Clinical Trial","INCLUSION CRITERIA\n\n1. The patient shall sign the informed consent.\n2. Age ≥ 18 years.\n3. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n4. Histologically or cytologically confirmed Stage III (per AJCC 9th) squamous or non-squamous non-small-cell lung cancer (NSCLC) deemed unresectable by the investigator.\n5. Tumours with mixed NSCLC histology must be categorised as either squamous or non-squamous on the basis of the predominant component. Tumours containing both NSCLC and small-cell lung cancer (SCLC) are excluded.\n6. \"Unresectable\" is defined as following: (1) Multistation or confluent metastasis in ipsilateral mediastinal lymph nodes (2)Contralateral or supraclavicular lymph node metastasis (N3) (3)Invasion of critical organs or major blood vessels (4)Extensive invasion of the chest wall and pleura (5)Special anatomical locations (6）Patient intolerance to lobectomy or pneumonectomy.\n7. At least one measurable lesion per RECIST v1.1.\n8. Adequate organ function meet the following standards (within 14 days before first dose, any blood components or growth factor drugs is not permitted):\n\n   * ANC count ≥ 1.5 × 10⁹\u002FL\n   * Platelet count ≥ 100 × 10⁹\u002FL\n   * Hemoglobin ≥ 90 g\u002FL\n   * Serum Cr ≤ 1.5 times of upper limit of normal (ULN) or calculated creatinine clearance (CLcr) ≥ 50 mL\u002Fmin\n   * Total bilirubin ≤ 1.5 × ULN (≤ 3 × ULN in Gilbert's syndrome)\n   * AST and ALT ≤ 2.5 × ULN\n   * INR or APPT ≤ 1.5 × ULN\n   * left ventricular ejection fraction (LVEF) ≥ 50 %\n9. Contraception and reproductive status:\n10. Fertile female patients must voluntarily use effective contraception during the study period and for at least 3 months after treatment completion, and urine or serum pregnancy test result within 72 hours prior to enrollment are negative and must not be breastfeeding. Male patients with female partners of childbearing potential must use effective contraception during the trial and for 3 months after the last dose of IBI363.\n\nEXCLUSION CRITERIA\n\n1. Non-squamous and squamous NSCLC with EGFR active mutation positive, ALK rearrangement, or any other driver mutation with an approved targeted therapy.\n2. History of other malignant tumors within five years or concurrently present, except adequately treated cervical carcinoma in situ, basal- or squamous-cell skin carcinoma, localized prostate cancer after radical prostatectomy, ductal carcinoma in situ after radical prostatectomy, or other tumor deemed cured by the investigator.\n3. Histologically confirmed the presence of small cell lung cancer component.\n4. Participants who have received any systemic anti-cancer treatment.\n5. Clinically significant cardiovascular or cerebrovascular disease, including:\n\n   1. Myocardial infarction or unstable angina within 6 months before first dose\n   2. Stroke or transient ischaemic attack within 6 months before first dose\n   3. Uncontrolled hypertension (systolic ≥ 160 mmHg and\u002For diastolic ≥ 100 mmHg) despite optimal therapy\n   4. Congestive heart failure (NYHA class III-IV)\n   5. Myocarditis\n6. Participants who were systemically treated with corticosteroids (prednisone or other corticosteroids \\>10 mg\u002F day) or other immunosuppressive agents within 2 weeks prior to first administration. In the absence of active autoimmune disease, inhaled or topical corticosteroids and adrenal hormone replacement therapy are permitted.\n7. Presence of any active autoimmune disease or history of autoimmune disease.\n8. Idiopathic pulmonary fibrosis, organizing pneumonia, drug pneumonia, or active pneumonia shown on CT during screening period have been or are currently present.\n9. History of allogeneic haematopoietic stem-cell or solid-organ transplantation.\n10. The subject has congenital or acquired immune deficiency (such as HIV infected persons).\n11. Active hepatitis (HBsAg positive and HBV DNA \\>the upper limit of normal value; HCV antibody and HCV RNA positive. Subjects who meet the following criteria may be enrolled: HBV-DNA \\\u003C500 IU\u002FmL measured within 28 days prior to study dosing, have received at least 4 weeks of standard antiviral therapy, and are willing to continue antiviral therapy throughout the study period.)\n12. Participants who are allergic to the test drug or any auxiliary materials.\n13. The vaccine was administered within 30 days before first dose or planned during treatment and up to 90 days after the last dose.\n14. Severe active infection within 2 weeks before first dose.\n15. Other factors that may increase study risk, interfere with results, or render the patient unsuitable per investigator judgment.",{"count":328,"type":22},43,[140],"This study is a single-arm, phase II clinical trial evaluating the safety and efficacy of IBI363 combined with chemotherapy as a neoadjuvant treatment of non-small cell lung cancer.",[332,333],"Unresectable Stage III Non-small Cell Lung Cancer","Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)","2026-02-12",{"date":336,"type":39},"2026-02-13",{"date":338,"type":39},"2026-01-07",{"date":340,"type":22},"2030-01-06",{"name":45,"class":46},{"id":343,"slug":344,"hasResults":12,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":4,"eligibilityCriteria":348,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":23,"phases":350,"briefSummary":351,"conditions":352,"keywords":354,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":130},"100624541","phase-2-efficacy-of-anti-ctla-4-antibody-combined-with-sintilimab-and-chemotherapy-as-neoadjuvant-therapy-for-resectable-stage-ii-iii-non-small-cell-lung-cancer-100624541","NCT07410975","Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer","Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer: A Phase II, Single-Arm Clinical Study","INCLUSION CRITERIA\n\n1. The patient shall sign the informed consent.\n2. Age ≥ 18 years.\n3. Histologically or cytologically confirmed non-small-cell lung cancer (NSCLC).\n4. No prior anticancer therapy, including (but not limited to) chemotherapy, immunotherapy or radiotherapy. Traditional Chinese medicine given for anticancer intent is permitted provided it was discontinued ≥ 2 weeks before first dose.\n5. Investigator-assessed resectable Stage II-IIIB (N3 excluded) NSCLC per AJCC 9th.\n6. Non-squamous NSCLC: no EGFR mutation, ALK rearrangement or any other driver mutation with an approved targeted agent. Squamous NSCLC: no known EGFR mutation, ALK rearrangement or other actionable driver mutation.\n7. PD-L1 expression negative (22C3 or E1L3N).\n8. ECOG performance status 0 or 1.\n9. Adequate organ function within 7 days before first dose:\n\n   * Haemoglobin ≥ 90 g\u002FL (no transfusion within 28 days)\n   * Absolute neutrophil count ≥ 1.5 × 10⁹\u002FL\n   * Platelet count ≥ 100 × 10⁹\u002FL (no platelet transfusion or IL-11 within 14 days)\n   * Creatinine clearance ≥ 60 mL\u002Fmin (Cockcroft-Gault)\n   * Total bilirubin ≤ 1.5 × ULN (≤ 2.5 × ULN in Gilbert's syndrome or hepatic metastases)\n   * ALT and AST ≤ 3 × ULN\n   * INR or aPTT ≤ 1.5 × ULN\n   * FEV\\> 2L, FEV1\\> 1L, FEV1\u002FFVC ≥ 70%, DLCO ≥ 70% predicted; or Investigator determination that pulmonary reserve is adequate for planned surgery.\n10. Fertile female must have a negative serum pregnancy test within 7 days before first dose.\n11. Fertile female and male patients with female partners of childbearing potential must use a highly effective contraceptive method (annual failure rate \\\u003C 1 %) from 7 days before first dose until 24 weeks after the last dose.\n\nEXCLUSION CRITERIA\n\n1. Major thoracic or abdominal surgery within 28 days before first dose or incomplete recovery from previous surgery.\n2. Participants who were systemically treated with corticosteroids (prednisone or other corticosteroids \\>10 mg\u002Fday) or other immunosuppressive agents for ≥ 7 consecutive days within 14 days before first dose. Except for inhaled or topical corticosteroids, or corticosteroid therapy at physiological replacement doses for adrenal insufficiency; short- courses (\\\u003C7 days) corticosteroid use is permitted for the prevention or treatment of non-autoimmune conditions;\n3. Participants who received live vaccines (including live attenuated vaccines) within 28 days before first dose.\n4. Current or prior interstitial pneumonia or pulmonary diseases requiring systemic glucocorticoids.\n5. Presence of any active autoimmune disease or history of autoimmune disease. Except in the following cases: Type 1 diabetes, stable hypothyroidism under hormone replacement therapy, psoriasis or vitiligo not requiring systemic treatment.\n6. Other malignancy within 5 years before first dose, except for tumors assessed by the investigator as cured.\n7. Uncontrolled comorbidities, including:\n\n   * Active hepatitis B (HBsAg positive and HBV DNA \\> 500 IU\u002FmL or \\> 2000 copies\u002FmL) or hepatitis C (HCV antibody and HCV RNA positive). Subjects with HBV DNA ≤ 500 IU\u002FmL who agree to antiviral prophylaxis are eligible.\n   * Known HIV infection or history of AIDS.\n   * Active tuberculosis.\n   * Active infection requiring systemic antibiotics for \\> 7 days within 28 days before first dose.\n   * Clinically significant cardiovascular disease: cerebrovascular accident within 6 months, symptomatic heart failure (NYHA class II-IV), unstable angina or myocardial infarction within 6 months, risk of QTc prolongation or arrhythmia.\n   * Urine protein qualitative≥ 2+, and 24-hour urine protein test \\> 1g\n8. History of allogeneic haematopoietic stem-cell or solid-organ transplantation.\n9. Hypersensitivity to antibody therapies (≥ grade 3 NCI-CTCAE v6.0), history of anaphylaxis, uncontrolled asthma, or significant drug allergies.\n10. Pregnancy or lactation.\n11. Other conditions that may affect the safety or compliance of drug therapy in this study include, but are not limited to, psychiatric disorders, uncontrolled large serosal cavity effusions, or moderate to large serosal cavity effusions requiring repeated drainage (recurring within 2 weeks after intervention), such as pleural effusion, pericardial effusion, or ascites cachexia.",{"count":257,"type":22},[140],"This study aims to evaluate the major pathologic response (MPR) rate of neoadjuvant therapy with sintilimab (PD-1 inhibitor) + IBI310 (anti-CTLA-4 antibody) + chemotherapy, and to assess the efficacy of this treatment strategy in patients with PD-L1-negative stage II - IIIB (excluding N3) NSCLC (according to AJCC 9th) scheduled for surgery.",[261,353],"NSCLC Stage III",[355,310,356],"CTLA-4","neoadjuvant","2026-02-06",{"date":336,"type":39},{"date":360,"type":39},"2026-01-10",{"date":362,"type":22},"2030-01-10",{"name":45,"class":46},{"id":365,"slug":366,"hasResults":12,"nctId":367,"briefTitle":368,"officialTitle":368,"acronym":369,"eligibilityCriteria":370,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":371,"targetDuration":4,"studyType":23,"phases":373,"briefSummary":374,"conditions":375,"keywords":377,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":383,"completionDateStruct":384,"leadSponsor":386,"locationsCount":130},"100623188","phase-4-intrapleural-bupivacaine-analgesia-for-postoperative-pain-management-after-minimally-invasive-video-assisted-thoracoscopic-surgery-a-randomized-controlled-trial-100623188","NCT07393386","Intrapleural Bupivacaine Analgesia for Postoperative Pain Management After Minimally Invasive Video-Assisted Thoracoscopic Surgery: A Randomized Controlled Trial","IBVATS","Inclusion Criteria:\n\n1. Patients scheduled for elective video-assisted thoracoscopic surgery\n2. Age≥18 years\n3. American Society of Anesthesiologists (ASA) physical status classification I-III\n\nExclusion Criteria:\n\n1. Pregnancy or breastfeeding\n2. History of chronic pain\n3. History of alcohol or opioid dependence\n4. Significant cardiopulmonary dysfunction, including heart failure or severe cardiac conduction abnormalities\n5. Coexisting central nervous system disorders\n6. Hepatic or renal dysfunction\n7. Known hypersensitivity to local anesthetics or opioids\n8. Local infection at or near the planned site of regional anesthesia, or systemic infection\n9. Language impairment or difficulty in communication\n10. Refusal to participate in the study or refusal to use patient-controlled analgesia\n11. Concurrent participation in another clinical trial",{"count":372,"type":22},249,[300],"Postoperative pain is common after video-assisted thoracoscopic surgery (VATS), with pleural irritation caused by chest tube placement being a major contributor. Inadequate pain control may impair respiratory function, delay postoperative recovery, and increase the risk of complications. However, effective and targeted analgesic strategies specifically addressing chest tube-related pain remain limited.\n\nThis is a single-center, prospective, randomized, double-blind, placebo-controlled superiority trial designed to evaluate the efficacy and safety of programmed intermittent intrapleural administration of bupivacaine at different concentrations for postoperative analgesia after VATS. A total of 249 patients undergoing VATS will be randomly assigned in a 1:1:1 ratio to receive intrapleural injections of 0.25% bupivacaine, 0.125% bupivacaine, or normal saline. The primary outcome is pain intensity during coughing within 48 hours after surgery. Secondary outcomes include pain intensity at rest, plasma bupivacaine concentrations, quality of postoperative recovery, cumulative opioid consumption, and postoperative inflammatory marker levels.\n\nThis study aims to provide evidence to inform analgesic strategies for chest tube-related pain following VATS and to clarify the optimal use and safety profile of intrapleural bupivacaine.",[376],"Pain Management",[378,379,380],"Postoperative pain","Thoracoscopic surgery","Intrapleural analgesia","2026-02-01",{"date":357,"type":39},{"date":381,"type":22},{"date":385,"type":22},"2028-06-30",{"name":45,"class":46},{"id":388,"slug":389,"hasResults":12,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":393,"eligibilityCriteria":394,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":395,"enrollmentInfo":396,"targetDuration":4,"studyType":23,"phases":398,"briefSummary":399,"conditions":400,"keywords":405,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":419,"locationsCount":420},"100623192","phase-2-acetohydroxamic-acid-combined-with-a-short-course-regimen-for-mdr-tb-aha-plus-100623192","NCT07393438","Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS)","Acetohydroxamic Acid Combined With a Short-Course Regimen for the Treatment of Multidrug-Resistant Tuberculosis: A Phase II Clinical Trial","AHA-PLUS","Inclusion Criteria:\n\n* Age 14 to \\\u003C 65 years, male or female\n* Confirmed rifampicin-resistant TB (RR-TB) or multidrug-resistant TB (MDR-TB) by molecular testing (e.g., Xpert MTB\u002FRIF) or drug susceptibility testing\n* Positive sputum culture for Mycobacterium tuberculosis or positive molecular test\n* Chest imaging consistent with active pulmonary TB, or histologically confirmed extrapulmonary TB (excluding CNS, osteoarticular, and disseminated TB)\n* Body weight ≥ 40 kg\n* Karnofsky Performance Status ≥ 50\n* Adequate laboratory parameters:\n\n  * Hemoglobin ≥ 8.0 g\u002FdL\n  * ANC ≥ 1000\u002Fmm³\n  * Platelets ≥ 75,000\u002Fmm³\n  * ALT\u002FAST ≤ 3 × ULN\n  * Total bilirubin ≤ 2 × ULN\n  * Creatinine clearance ≥ 30 mL\u002Fmin\n* QTcF interval \\\u003C 450 ms (male) or \\\u003C 470 ms (female)\n* HIV-negative, confirmed by approved testing\n* No prior exposure to bedaquiline, delamanid, or linezolid for more than 1 month\n* Female participants of childbearing potential must agree to use effective contraception and have a negative pregnancy test\n* Signed informed consent\n\nExclusion Criteria:\n\n* Central nervous system TB (e.g., TB meningitis), osteoarticular TB, or disseminated\u002Fmiliary TB\n* Known allergy or serious adverse reaction to any study drug or background regimen component\n* Known resistance to bedaquiline, delamanid, or linezolid\n* Use of anti-TB drugs within the past 30 days that may interfere with study assessments, except in documented treatment failure cases\n* Severe comorbidities, including:\n\n  * NYHA Class III-IV heart failure\n  * History or risk factors for Torsades de Pointes\n  * Child-Pugh B or C cirrhosis\n  * Uncontrolled diabetes (HbA1c \\> 10%)\n  * Active malignancy\n* Current use of QT-prolonging medications that cannot be substituted\n* Current use of MAO inhibitors or serotonergic drugs\n* BMI \\\u003C 17 kg\u002Fm² with severe malnutrition\n* Grade 3-4 peripheral neuropathy at baseline\n* Pregnant or breastfeeding women\n* Any condition that, in the investigator's judgment, may interfere with study completion or data interpretation","65 Years",{"count":397,"type":22},120,[140],"This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the safety, tolerability, and preliminary efficacy of acetohydroxamic acid (AHA) capsules combined with short-course regimens (BDLLfxC or BDCZ) in patients with multidrug-resistant tuberculosis (MDR-TB).\n\nThe primary objectives are to assess the safety and tolerability of AHA combined with short-course regimens, and to determine the recommended phase II dose (RP2D) of AHA.\n\nThe secondary objectives include evaluating the 8-week sputum culture conversion rate, pharmacokinetic parameters, and exploring DNA damage repair biomarkers as potential indicators of treatment response.",[401,402,403,404],"Multidrug-Resistant Tuberculosis","Rifampicin-resistant Tuberculosis","MDR-TB","RR-TB",[406,407,408,409,410,411,412],"Acetohydroxamic Acid","Short-Course Regimen","BDLLfxC","BDCZ","DNA Repair","RP2D","Phase II","2026-01-31",{"date":357,"type":39},{"date":416,"type":22},"2026-02-21",{"date":418,"type":22},"2028-11-30",{"name":45,"class":46},2,{"id":422,"slug":423,"hasResults":12,"nctId":424,"briefTitle":425,"officialTitle":425,"acronym":4,"eligibilityCriteria":426,"healthyVolunteers":427,"sex":17,"minAge":428,"maxAge":429,"enrollmentInfo":430,"targetDuration":4,"studyType":432,"phases":4,"briefSummary":433,"conditions":434,"keywords":435,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":446,"locationsCount":447},"100621850","a-multi-modal-integrating-imaging-and-cell-free-dna-methylation-in-lung-cancer-early-detection-cme-lung-a-multi-center-observational-study-100621850","NCT07375979","A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-center, Observational Study","Inclusion Criteria:\n\n* 40-74 years old\n* Clinically and\u002For pathologically diagnosed cancer\n* No prior or undergoing any systemic or local antitumor therapy, including but not limited to surgical resection, radiochemotherapy, endocrinotherapy, targeted therapy, immunotherapy, interventional therapy, etc.\n* Able to provide a written informed consent and willing to comply with all part of the protocol procedures\n\nExclusion Criteria:\n\n* Pregnancy or lactating women\n* Known prior or current diagnosis of other types of malignancies comorbidities\n* Severe acute infection (e.g. severe or critical COVID-19, sepsis, etc.) or febrile illness (body temperature of ≥ 38.5 °C) within 14 days prior to screen\n* Recipients of organ transplant or prior bone marrow transplant or stem cell transplant\n* Recipients of blood transfusion within 30 days prior to screen\n* Recipients of therapy in past 14 days prior to screen, including oral or IV antibiotics, glucocorticoid, azacitidine, decitabine, procainamide, hydrazine, arsenic trioxide\n* Unsuitable for this trial determined by the researchers\n* Low-quality samples: images only partially showing the lungs or in lateral decubitus position, unreadable due to severe motion artifacts\u002Fmetal artifacts, or with missing critical metadata\n\nInclusion Criteria for Control Arm Participants:\n\n* 40-74 years old\n* Without confirmed cancer diagnosis\n* Able to provide a written informed consent and willing to comply with all part of the protocol procedures\n\nExclusion Criteria for Control Arm Participants:\n\n* Pregnancy or lactating women\n* Known prior or current diagnosis of other types of malignancies comorbidities\n* Severe acute infection (e.g. severe or critical COVID-19, sepsis, etc.) or febrile illness (body temperature of ≥ 38.5 °C) within 14 days prior to screen\n* Recipients of organ transplant or prior bone marrow transplant or stem cell transplant\n* Recipients of blood transfusion within 30 days prior to screen\n* Recipients of therapy in the past 14 days prior to screen, including oral or IV antibiotics, glucocorticoid, azacitidine, decitabine, procainamide, hydrazine, arsenic trioxide\n* Unsuitable for this trial determined by the researchers\n* Low-quality samples: images only partially showing the lungs or in lateral decubitus position, unreadable due to severe motion artifacts\u002Fmetal artifacts, or with missing critical metadata",true,"40 Years","74 Years",{"count":431,"type":22},14300,"OBSERVATIONAL","This study is a multi-center, observational study aiming to develop an early screening multi-model for detecting lung cancer signals through the integration of imaging (non-contrast CT) and blood testing (cfDNA methylation).",[236],[436,437,438],"multi-modal","CT and cfDNA methylation","lung cancer early detection","2026-01-21",{"date":441,"type":39},"2026-01-29",{"date":443,"type":22},"2026-02-05",{"date":445,"type":22},"2026-09-01",{"name":45,"class":46},7,{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":4,"eligibilityCriteria":454,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":455,"targetDuration":457,"studyType":432,"phases":4,"briefSummary":458,"conditions":459,"keywords":460,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":130},"100618232","patient-derived-tumor-like-cell-cluster-model-based-precision-treatment-strategy-on-non-small-cell-lung-cancer-100618232","NCT07328945","Patient-derived Tumor-like Cell Cluster Model-based Precision Treatment Strategy on Non-small Cell Lung Cancer","Patient-derived Tumor-like Cell Cluster Model-based Precision Treatment Strategy on Non-small Cell Lung Cancer: a Prospective, Observational Study","Inclusion Criteria:\n\n1. Age: ≥18 years and ≤80 years;\n2. Non-small cell lung cancer diagnosed by pathology (including histology or cytology);\n3. Having measurable lesions (according to RECIST 1.1 criteria, the long diameter of CT scan of tumour lesion is ≥10mm, the short diameter of CT scan of lymph node lesion is ≥15mm, the thickness of scanning layer is not more than 5mm, and the measurable lesion has not received local treatment such as radiotherapy, cryotherapy, etc.);\n4. ECOG PS: 0-2 points;\n5. Expected survival ≥ 3 months;\n6. Adequate hepatic function, defined as total bilirubin levels ≤ 1.5 times the upper limit of normal (ULN) and alanine aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤ 2.5 times the ULN in all patients;\n7. Adequate renal function, defined as creatinine clearance ≥ 50 ml\u002Fmin (Cockcroft-Gault formula);\n8. Adequate coagulation function, defined as International Normalised Ratio (INR) or Prothrombin Time (PT) ≤ 1.5 times ULN; if the subject is on anticoagulant therapy, as long as the INR\u002FPT is within the range formulated for the anticoagulant drug;\n9. For female subjects of childbearing potential, a negative urine or serum pregnancy test should be presented within 3 days prior to receiving the first dose of study drug, or a blood pregnancy test will be requested if the urine pregnancy test result cannot be confirmed as negative;\n10. If there is a risk of conception, male and female patients are required to use highly effective contraception (i.e., a method with a failure rate of less than 1% per year) for at least 180 days after discontinuation of trial treatment; NOTE: Abstinence is acceptable as a method of contraception if abstinence is the subject's usual lifestyle and preferred method of contraception;\n11. Subjects voluntarily enroll in the study, sign a written informed consent prior to the implementation of any trial-related process, are compliant, and cooperate with follow-up visits.\n\nExclusion Criteria:\n\n1. Currently participating in an interventional clinical study treatment, or have received another investigational drug or investigational device within 4 weeks prior to the first dose;\n2. Have received a proprietary medicine with an anti-tumor indication or an immunomodulatory drug (thymidine, interferon, interleukin, etc.) within 2 weeks prior to the first dose, or have received major surgical treatment within 3 weeks prior to the first dose;\n3. Presence of active hemoptysis, active diverticulitis, abdominal abscess, gastrointestinal obstruction and peritoneal metastases requiring clinical intervention;\n4. Known or screening test findings of active central nervous system (CNS) metastases and\u002For carcinomatous meningitis;\n5. Has received a solid organ or blood system transplant;\n6. Class III-IV congestive heart failure (New York Heart Association classification) with poorly controlled and clinically significant arrhythmias;\n7. Any arterial thrombosis, embolism or ischemia such as myocardial infarction, unstable angina, cerebrovascular accident or transient ischemic attack within 6 months prior to enrolment for treatment. History of deep vein thrombosis, pulmonary embolism, or any other serious thromboembolism within 3 months prior to enrolment (implantable IV port or catheter-derived thrombosis, or superficial venous thrombosis are not considered \"serious\" thromboembolism);\n8. Active autoimmune disease requiring systemic therapy (e.g., disease-modifying drugs, corticosteroids, or immunosuppressants) within 2 years prior to the first dose. Alternative therapies (e.g., thyroxine, insulin, or physiological doses of corticosteroids for adrenal or pituitary insufficiency) are not considered systemic therapy;\n9. Patients requiring long-term systemic corticosteroids. Patients requiring intermittent use of bronchodilators, inhaled corticosteroids, or locally injected corticosteroids due to COPD, asthma may be enrolled;\n10. Diagnosis of other malignancy within 5 years prior to the first dose, excluding radically treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and\u002For radically resected carcinoma in situ, and if diagnosed with other malignancy or lung cancer more than 5 years prior to the dose, pathological or cytological diagnosis of recurrent metastatic lesions is required;\n11. Known psychiatric or substance abuse conditions that may have an impact on compliance with the trial requirements;\n12. Known history of human immunodeficiency virus (HIV) infection (i.e., HIV 1\u002F2 antibody positive), known syphilis infection (syphilis antibody positive), active tuberculosis;\n13. untreated active hepatitis B; Note: Subjects with hepatitis B who meet the following criteria are also eligible for enrolment: HBV viral load must be \\\u003C1000 copies\u002Fml (200 IU\u002Fml) or below the lower limit of detection prior to the first dose of drug, and subjects should be treated with anti-HBV therapy to avoid viral reactivation for the entire duration of the study chemotherapeutic agent treatment. For subjects with anti-HBc (+), HBsAg (-), anti-HBs (-) and HBV viral load (-), prophylactic anti-HBV therapy is not required but close monitoring of viral reactivation is needed;\n14. Subjects with active HCV infection (HCV antibody positive and HCV-RNA levels above the lower limit of detection);\n15. Live vaccination within 30 days prior to the first dose; NOTE: It is permissible to receive injectable inactivated viral vaccine against seasonal influenza; however, it is not permissible to receive live attenuated influenza vaccine administered intranasally;\n16. The presence of abnormal results from a medical history, disease, treatment, or laboratory that could interfere with the results of the trial, prevent the subject from participating in the study throughout its duration, or where participation in the study is not, in the opinion of the Investigator, in the best interest of the subject;\n17. Local or systemic disease, or secondary reactions to cancer, not due to malignancy and which may result in a higher medical risk and\u002For uncertainty in the evaluation of survival.\n18. Persons who, in the opinion of the investigator, are not suitable for inclusion.",{"count":456,"type":22},250,"1 Year","This trial is a prospective, observational study of non-small cell lung cancer that aims to evaluate the feasibility, preliminary efficacy and safety of patient-derived tumor-like cell cluster model in guiding the precision treatment strategy.",[214],[461,462],"Patient-derived Tumor-like Cell Cluster","Precision Treatment Strategy","2026-01-08",{"date":465,"type":39},"2026-01-09",{"date":467,"type":39},"2023-12-01",{"date":469,"type":22},"2028-07",{"name":45,"class":46},{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":4,"eligibilityCriteria":477,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":478,"targetDuration":4,"studyType":23,"phases":480,"briefSummary":481,"conditions":482,"keywords":485,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":491,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":496,"locationsCount":130},"100617779","phase-2-neoadjuvant-sacituzumab-tirumotecan-and-limertinib-for-potentially-resectable-stage--egfr-mutant-non-small-cell-lung-cancer-100617779","NCT07323056","Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer","Sacituzumab Tirumotecan and Limertinib for Conversion Therapy in Locally Advanced Potentially Resectable EGFR-mutant Non-small Cell Lung Cancer: A Prospective, Single-arm, Exploratory Clinical Study","Inclusion Criteria:\n\n* Sign the informed consent form\n* The age of the subjects is over 18 years old\n* Patients with non-small cell lung cancer (NSCLC) with EGFR mutation confirmed by pathology\n* Confirmed as locally advanced NSCLC (IIIA, IIIB, IIIC) by chest CT, PET-CT or\u002Fand EBUS, and MDT discussion concludes that immediate local surgery is not suitable\n* Have not received systematic anti-tumor treatment before\n* The researcher confirms at least one measurable lesion according to RECIST 1.1 criteria\n* Good lung function and able to tolerate surgical treatment\n* ECOG score is 0 to 1\n\nExclusion Criteria:\n\n* Allergy to Sacituzumab Tirumotecan or any of its excipients\n* Patients allergic to Limertinib or any of its excipients\n* Patients with a history of other primary tumors; patients with a history of allogeneic organ transplantation\n* Major surgery within 4 weeks before the first dose (excluding diagnostic biopsy)\n* Patients with drug addiction such as drug abuse, long-term alcohol abuse, AIDS or HIV carriers\n* Patients with active or previously had and may recur autoimmune diseases\n* Currently receiving systemic hormone therapy (such as equivalent to more than 10 mg of prednisone per day or any other form of immunosuppressive therapy within 14 days before the first dose)\n* Patients who have received any EGFR-TKI or TROP2 ADC treatment before",{"count":479,"type":22},36,[140],"This study is a prospective, single-arm, exploratory clinical research aimed at evaluating the efficacy and safety of lucetamab in combination with leucovorin in the conversion therapy of locally advanced potentially resectable EGFR mutation-positive non-small cell lung cancer, providing more robust clinical evidence for the improvement of treatment modalities for EGFR-mutated locally advanced NSCLC. At the same time, it seeks to identify biomarkers that can predict the therapeutic effect of the combination of lucetamab and leucovorin, offering more precise guidance for the selection of clinical treatment plans and enabling patients to receive the optimal treatment regimen.",[483,484],"EGFR-mutant Non-small Cell Lung Cancer","Potentially Resectable",[486,487,488,489],"non-small cell lung cancer","EGFR-mutant","Sacituzumab Tirumotecan","Limertinib","2026-01-06",{"date":338,"type":39},{"date":493,"type":22},"2026-01-01",{"date":495,"type":22},"2026-12-01",{"name":45,"class":46},{"id":498,"slug":499,"hasResults":12,"nctId":500,"briefTitle":501,"officialTitle":502,"acronym":4,"eligibilityCriteria":503,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":504,"targetDuration":4,"studyType":23,"phases":506,"briefSummary":507,"conditions":508,"keywords":513,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":517,"lastUpdatePostDateStruct":518,"startDateStruct":520,"completionDateStruct":522,"leadSponsor":524,"locationsCount":130},"100574393","phase-2-post-line-treatment-with-teniposide-for-c-myc-driven-extensive-stage-small-cell-lung-cancer-100574393","NCT06758700","Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer","Phase II Clinical Study to Evaluate the Efficacy and Safety of Teniposide as a Post-Line Therapy for c-Myc-Driven Extensive-Stage Small Cell Lung Cancer","Inclusion Criteria:\n\n1. extensive stage small cell lung cancer\n2. Progression after receiving at least one chemotherapy drug treatment in the past;\n3. ECOG score 0-1\n4. c-Myc-driven\n5. Expected survival period ≥3 months\n6. Age: 18-75 years old;\n7. The informed consent form complies with the ICH-GCP principles.\n\nExclusion Criteria:\n\n1. No measurable lesions\n2. Other severe and persistent diseases or organ system dysfunction;\n3. Women planning pregnancy or men planning family planning;\n4. Women who are pregnant or breastfeeding;\n5. Those who cannot follow the research protocol provided by the investigator.",{"count":505,"type":22},15,[140],"The study is being conducted to investigate the efficacy and safety of teniposide in patients with extensive-stage small cell lung cancer who have failed standard treatment and with high expression of the c-Myc-driven FBXW2\u002FMYC gene. Based on the results, the study will explore the correlation between the expression of FBXW2\u002FMYC and the efficacy of teniposide.",[509,510,511,512],"Extensive-stage Small Cell Lung Cancer (ES-SCLC)","Thoracic Neoplasms","Lung Neoplasms","Lung Diseases",[514,515,412,516],"c-Myc","SCLC","Post-line","2025-11-30",{"date":519,"type":39},"2025-12-05",{"date":521,"type":39},"2025-02-07",{"date":523,"type":22},"2026-12-31",{"name":45,"class":46},{"id":526,"slug":527,"hasResults":12,"nctId":528,"briefTitle":529,"officialTitle":529,"acronym":4,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":88,"enrollmentInfo":531,"targetDuration":4,"studyType":432,"phases":4,"briefSummary":533,"conditions":534,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":536,"lastUpdatePostDateStruct":537,"startDateStruct":539,"completionDateStruct":541,"leadSponsor":542,"locationsCount":543},"100611691","synthetic-pet-from-ct-improves-precision-diagnosis-and-treatment-of-lung-cancer-a-prospective-observational-multicenter-study-100611691","NCT07243873","Synthetic PET From CT Improves Precision Diagnosis and Treatment of Lung Cancer: a Prospective, Observational, Multicenter Study","Inclusion Criteria:\n\n1. Patients with non-small cell lung cancer scheduled to undergo PET-CT and pathological examinations;\n2. Voluntarily participate and sign an informed consent form;\n\nExclusion Criteria:\n\n1. History of other malignant tumours;\n2. Image artefacts;\n3. Without pathological diagnostic information;\n4. Without paired CT and FDG-PET scan images.",{"count":532,"type":22},10000,"This study aims to synthesise PET data that preserves biological relevance and adds clinical value to the diagnosis and prognosis of lung cancer by establishing anatomical-to-metabolic mapping based on paired diagnostic CT and FDG-PET scans, thereby prospectively validating the clinical utility of the model.",[236,535],"PET-CT","2025-11-20",{"date":538,"type":39},"2025-11-24",{"date":540,"type":22},"2025-12-01",{"date":495,"type":22},{"name":45,"class":46},5,{"id":545,"slug":546,"hasResults":12,"nctId":547,"briefTitle":548,"officialTitle":548,"acronym":4,"eligibilityCriteria":549,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":88,"enrollmentInfo":550,"targetDuration":4,"studyType":432,"phases":4,"briefSummary":552,"conditions":553,"keywords":555,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":564,"completionDateStruct":566,"leadSponsor":568,"locationsCount":569},"100585261","the-c-bridge-study-china-bronchiectasis-research-involving-databases-genomics-and-endotyping-100585261","NCT06900062","The C-BRIDGE Study: China Bronchiectasis Research Involving Databases, Genomics, and Endotyping","Inclusion Criteria:\n\n* A prior CT scan confirming bronchiectasis, accompanied by a compatible clinical syndrome including cough, sputum production, and\u002For recurrent respiratory tract infections.\n* At the screening visit, participants must have been clinically stable for 4 weeks, defined as no antibiotic or corticosteroid treatment for a pulmonary exacerbation in the preceding 4 weeks.\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Age under 18 years\n* Patients with active tuberculosis\n* Use of antibiotics or corticosteroids for a pulmonary exacerbation within the past 4 weeks",{"count":551,"type":22},1500,"Bronchiectasis is a heterogeneous airway disease with diverse causes, making precise diagnosis, prognosis, and treatment response prediction challenging. Identifying patient subgroups (phenotypes) and molecular profiles (endotypes) can enhance individualized assessment and management. While prior studies, primarily in European populations, have identified key phenotypes and endotypes, their relevance to Chinese patients remains unclear due to geographic and clinical differences. Specific causes of bronchiectasis, such as allergic bronchopulmonary aspergillosis (ABPA) and primary ciliary dyskinesia (PCD), may also exhibit distinct pathophysiology requiring further exploration. The C-BRIDGE Study seeks to characterize phenotypes and endotypes in Chinese bronchiectasis patients during stable disease and exacerbations, evaluate differences in clinical outcomes across these subgroups, and develop personalized medicine strategies based on these findings, applicable in China and globally.\n\nPrimary Objective: To identify molecular endotypes of bronchiectasis that accurately predict prognosis and guide treatment responses.\n\nSecondary Objectives:\n\nTo characterize molecular endotypes of stable bronchiectasis in Chinese patients.\n\nTo define molecular endotypes of bronchiectasis exacerbations in Chinese patients.\n\nTo investigate molecular endotypes specific to allergic bronchopulmonary aspergillosis (ABPA).\n\nTo explore genotypes and inflammatory endotypes of cystic fibrosis (CF) and primary ciliary dyskinesia (PCD) in Chinese patients.\n\nTo validate candidate biomarkers for stable and exacerbation endotypes to support stratified medicine.\n\nTo conduct in vivo or in vitro proof-of-concept studies using phenotypic data to identify patient subgroups likely to benefit from specific pharmacological interventions.\n\nStudy Design: This observational cohort study will link identified patient subgroups with meaningful clinical outcomes to inform prognosis and optimize treatment strategies.",[554],"Bronchiectasis Adult",[556,557,558,559,560],"bronchiectasis","phenotype","endotype","multi-omics","precision medicine","2025-11-19",{"date":563,"type":39},"2025-11-25",{"date":565,"type":39},"2025-04-06",{"date":567,"type":22},"2029-01-31",{"name":45,"class":46},9,{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":575,"acronym":4,"eligibilityCriteria":576,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":577,"targetDuration":4,"studyType":23,"phases":578,"briefSummary":579,"conditions":580,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":584,"lastUpdatePostDateStruct":585,"startDateStruct":586,"completionDateStruct":587,"leadSponsor":589,"locationsCount":4},"100611032","phase-2-ensartinib-after-chemoradiotherapy-in-stage-iii-alk-mutated-nsclc-100611032","NCT07235306","Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC","Ensartinib for the Treatment of Patients With ALK-Mutated Stage III Unresectable NSCLC: A Multicenter, Randomized Controlled, Double-blind Clinical Study","Inclusion Criteria:\n\n* Male or female aged at least 18 years\n* Histologically or cytologically confirmed Stage III unresectable non-small cell lung cancer (NSCLC) with curative treatment intent\n* ALK mutations assessed by FISH, IHC, or NGS\n* ECOG Performance Status of 0 or 1\n* Completion of platinum-based concurrent or sequential chemoradiotherapy as per protocol requirements\n* Chemoradiotherapy must have been completed ≤ 6 weeks prior to randomization\n* No disease progression during or after chemoradiotherapy\n* Life expectancy \\> 12 weeks\n* Women of childbearing potential must have a negative urine pregnancy test within 7 days prior to initiation of treatment\n* Signed informed consent form obtained from the patient or their legally authorized representative\n* Male and female patients of childbearing potential agree to use highly effective contraception methods from before entering the trial, throughout the study, and until 8 weeks after discontinuation of study treatment\n\nExclusion Criteria:\n\n* Mixed histology of small cell and non-small cell lung cancer\n* Symptomatic pneumonitis following chemoradiotherapy that has not resolved to ≤ Grade 1 (per CTCAE criteria) prior to randomization;\n* Any unresolved toxicity from prior chemoradiotherapy with toxicity ≥ Grade 2 (according to CTCAE criteria);\n* Poor cardiac function, including but not limited to any of the following:\n\n  * Mean resting corrected QT interval (QTc) \\> 470 msec (obtained from 3 ECGs);\n  * Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG;\n  * Any factors that increase the risk of QTc prolongation or arrhythmic events, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or concomitant use of any known drugs that prolong the QT interval and may lead to Torsades de Pointes;\n* Inadequate bone marrow reserve or organ function;\n* History of other malignant malignancies, except for adequately treated non-melanoma skin cancer or malignant lentigo, cured carcinoma in situ, or other solid tumors cured \\> 5 years ago with no evidence of disease and considered by the treating physician to have a low risk of recurrence;\n* Severe or uncontrolled systemic diseases: including uncontrolled hypertension and active bleeding tendency; or active infections, including hepatitis B, hepatitis C, and human immunodeficiency virus (HIV);\n* Refractory nausea and vomiting, chronic gastrointestinal disease, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of ensartinib;\n* Any prior chemotherapy, radiotherapy, immunotherapy, or investigational drug therapy beyond the definitive treatment for locally advanced disease;\n* Prior treatment with any ALK tyrosine kinase inhibitor (ALK-TKI);\n* Major surgery within 4 weeks prior to the first dose of study drug;\n* Current use of medications known to be strong inducers of CYP3A4 (which cannot be discontinued at least 3 weeks prior to the first dose of study drug);\n* Known hypersensitivity to ensartinib or any excipient in this product;\n* Pregnant or lactating women;\n* History of definite neurological or psychiatric disorders, including epilepsy or dementia;\n* Any other condition that, in the judgment of the investigator, would make the subject unsuitable for participation in the study.",{"count":210,"type":22},[140],"The PACIFIC study established the standard of care for immunotherapy consolidation after chemoradiotherapy (CRT) in patients with unresectable stage III non-small cell lung cancer (NSCLC). However, its benefit is limited in patients with driver gene mutations. The LAURA study established a new paradigm of targeted consolidation therapy after CRT for patients with EGFR mutations. Although retrospective data support the efficacy of ALK-TKIs, no randomized controlled trial (RCT) has clearly demonstrated the value of ALK-TKI maintenance therapy after CRT. This study adopts a multicenter, randomized, double-blind, placebo-controlled design aimed at evaluating the efficacy and safety of ensartinib in patients with ALK-positive unresectable stage III NSCLC.",[353,581,582,583],"Ensartinib","Chemoradiotherapy","ALK","2025-11-17",{"date":561,"type":39},{"date":540,"type":22},{"date":588,"type":22},"2031-12-31",{"name":45,"class":46},{"id":591,"slug":592,"hasResults":12,"nctId":593,"briefTitle":594,"officialTitle":595,"acronym":596,"eligibilityCriteria":597,"healthyVolunteers":12,"sex":17,"minAge":186,"maxAge":187,"enrollmentInfo":598,"targetDuration":4,"studyType":23,"phases":600,"briefSummary":601,"conditions":602,"keywords":603,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":608,"lastUpdatePostDateStruct":609,"startDateStruct":611,"completionDateStruct":613,"leadSponsor":615,"locationsCount":130},"100606004","phase-3-segmentectomy-vs-lobectomy-for-2---3cm-iaslc-grade-1-2-lung-adenocarcinoma-a-multi-center-rct-100606004","NCT07169903","Segmentectomy vs Lobectomy for 2 - 3cm IASLC Grade 1-2 Lung Adenocarcinoma: A Multi-center RCT","Comparison of Segmentectomy Versus Lobectomy for Lung Adenocarcinoma 2 - 3cm With IASLC Grade 1 - 2 by Intraoperative Frozen Sections: A Prospective and Multi - Center Randomized Controlled Trial Study","STAR012","1. Initial Registration (1.1) Inclusion Criteria: 1. Aged 20 to 79 years, regardless of gender. 2. Preoperative CT or PET-CT suggests: ① Imaging diameter of 2-3 cm.\n\n   * Suspicion of non-small cell lung cancer (NSCLC).\n\n     * Solitary nodule or concomitant lesions with microinvasion or below.\n\n       * Primary tumor not located in the middle lobe.\n\n         * No suspected lymph node involvement. 3. Preoperative CT lung window (window level -700HU, window width 1500HU) indicates the nodule is predominantly solid, i.e., the consolidation-to-tumor ratio (CTR) is greater than 0.5 (CTR \\> 0.5).\n\n           4\\. Good lung function (FEV1 \\> 1.5 L or FEV1% ≥ 60%), tolerable for both segmentectomy and lobectomy.\n\n           5\\. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2. 6. Voluntary participation with signed informed consent, able to comply with study visit plans and other protocol requirements.\n\n           7\\. No history of ipsilateral thoracotomy; video-thoracoscopic examination meets the criteria.\n\n           8\\. No history of chemotherapy or radiotherapy, including treatment for other cancers. Eligible if more than 5 years have passed since completion of perioperative adjuvant chemotherapy. Eligible if there is a history of or ongoing hormone therapy.\n\n           9\\. All the following laboratory test results are eligible (all laboratory tests use the latest results within 28 days before initial registration; laboratory tests on the same day within 4 weeks before initial registration are allowed):\n           * White blood cell count ≥ 3000\u002Fmm³.\n   * Hemoglobin ≥ 8.0 g\u002FdL (without blood transfusion within 28 days before initial registration).\n\n     * Platelet count ≥ 10×10⁴\u002Fmm³.\n\n       * AST ≤ 100 IU\u002FL.\n\n         ⑤ ALT ≤ 100 IU\u002FL.\n\n         ⑥ Total bilirubin ≤ 2.0 mg\u002FdL.\n\n         ⑦ Serum creatinine ≤ 1.5 mg\u002FdL. 10. The patient has signed a written informed consent. (1.2) Exclusion Criteria:\n         1. Active bacterial or fungal infection (confirmed by imaging diagnosis or bacteriological examination with fever \\>38°C).\n         2. Multiple active cancers (synchronous or metachronous multiple primary cancers, excluding in situ carcinoma or intramucosal cancer lesions considered cured by local treatment; such lesions are not included in active multiple cancers).\n         3. Patients with severe impairment of cardiac, hepatic, or renal function (cardiac function grade 3-4; ALT and\u002For AST more than 3 times the upper limit of normal; Cr exceeding the upper limit of normal).\n         4. Patients with concomitant other malignant tumors or hematological diseases.\n         5. Pregnant, planning to become pregnant, or lactating female patients (diagnosed with early pregnancy when urine HCG \\>2500 IU\u002FL).\n         6. Any form of antitumor therapy before tumor resection, including interventional chemotherapy embolization, ablation, radiotherapy, chemotherapy, and molecular targeted therapy.\n         7. Patients who participated in other tumor-related clinical trials within the past three months.\n         8. Preoperative CT suggests ground-glass predominant nodules (CTR \\\u003C 0.5).\n         9. Patients with positive lymph nodes indicated by preoperative imaging or lymph node puncture (clinical N stage = 1 or 2).\n         10. Patients with tumors near the hilum who cannot undergo segmentectomy.\n         11. Patients deemed unsuitable for enrollment by the investigator.\n2. Intraoperative Secondary Registration (2.1) Inclusion Criteria: 1. Intraoperative frozen section indicates invasive lung adenocarcinoma with International Association for the Study of Lung Cancer (IASLC) grade 1-2 (\\\u003C20% pathological high-grade subtypes).\n\n2\\. Intraoperative frozen section shows negative surgical margins. 3. Intraoperative exploration reveals no severe adhesions or lymph node inflammatory changes (adhesions of pulmonary vessels or bronchi), confirming feasibility for both lobectomy and segmentectomy.\n\n(2.2) Exclusion Criteria:\n\n1. Patients with IASLC grade 3 (≥20% pathological high-grade subtypes) indicated by intraoperative frozen section.\n2. Patients confirmed with in situ carcinoma or microinvasive adenocarcinoma by intraoperative frozen section.\n3. Patients with preoperative findings of distant metastasis or pleural\u002Fascitic effusion.",{"count":599,"type":22},587,[59],"This study is a prospective, multicenter randomized controlled trial (RCT) designed to compare the efficacy of segmentectomy and lobectomy for invasive lung adenocarcinoma with a diameter of 2-3 cm and intraoperative frozen section-confirmed IASLC pathological new grade 1-2. The non-inferiority of segmentectomy is primarily evaluated by 5-year relapse-free survival (RFS) and overall survival (OS) after surgery, while secondary endpoints include pulmonary function preservation, perioperative complications, etc. With a planned enrollment of 587 patients over a 3-year recruitment period and a 5-year follow-up, this study aims to identify an optimized surgical approach.",[193],[604,605,193,606,607],"Segmentectomy","Lobectomy","IASLC Grade","Randomized Controlled Trial","2025-09-10",{"date":610,"type":39},"2025-09-12",{"date":612,"type":22},"2025-10-01",{"date":614,"type":22},"2033-12-31",{"name":45,"class":46},{"id":617,"slug":618,"hasResults":12,"nctId":619,"briefTitle":620,"officialTitle":621,"acronym":622,"eligibilityCriteria":623,"healthyVolunteers":12,"sex":624,"minAge":18,"maxAge":625,"enrollmentInfo":626,"targetDuration":4,"studyType":23,"phases":628,"briefSummary":629,"conditions":630,"keywords":632,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":637,"startDateStruct":639,"completionDateStruct":640,"leadSponsor":642,"locationsCount":130},"100594513","efficacy-and-safety-of-huanjingjian-decoction-in-women-with-premature-ovarian-insufficiency-100594513","NCT07020429","Efficacy and Safety of Huanjingjian Decoction in Women With Premature Ovarian Insufficiency","Efficacy and Safety of the Traditional Chinese Herbal Formula Huanjingjian Decoction in Women With Premature Ovarian Insufficiency: a Randomised Controlled Trial","EAST-HOPE","Inclusion Criteria:\n\n* Age between 18 and 39 years\n* Meet the diagnostic criteria for Premature Ovarian Insufficiency (POI) according to the 2024 ESHRE Guideline on Premature Ovarian Insufficiency\n\nExclusion Criteria:\n\n* Menstrual disorders attributable to congenital gonadal dysgenesis or acquired structural pathologies;\n* Menstrual irregularities secondary to endocrine disorders, including polycystic ovary syndrome (PCOS), hyperprolactinemia, dysfunctional uterine bleeding (DUB), gonadal hormone deficiency, hyperthyroidism, and other related endocrine conditions;\n* Oligomenorrhea or amenorrhea induced by surgical or medical interventions, such as chemotherapy, pelvic radiotherapy, ovarian cystectomy, ovarian drilling, ovarian wedge resection, salpingectomy, tubal ligation, pelvic abscess surgery, or uterine artery embolization;\n* History of abnormal vaginal bleeding accompanied by clinically significant findings on endometrial biopsy, or unexplained irregular vaginal bleeding within the preceding 12 months;\n* Suspected cervical malignancy or precancerous cervical lesions, suspected malignant breast tumors, or a known or suspected history of hormone-dependent tumors or malignancies;\n* Previous or current history of deep vein thrombosis (DVT), pulmonary embolism, thrombotic disorders, or cerebrovascular events (stroke);\n* Presence of uncontrolled and\u002For undiagnosed systemic diseases that could confound study results or compromise patient safety, including severe hepatic, renal, cardiac, or neurological disorders;\n* Known hypersensitivity or allergy to any study-related medications;\n* Pregnancy or lactation;\n* Participation in other clinical trials within the last 3 months;\n* Failure or refusal to provide written informed consent.","FEMALE","39 Years",{"count":627,"type":22},276,[25],"Study Summary\n\nThis clinical trial aims to evaluate the efficacy and safety of the traditional Chinese herbal formula Huanjingjian decoction in women with premature ovarian insufficiency (POI). The study is designed to address the following key questions:\n\n1. Does Huanjingjian decoction improve clinical symptoms in patients with POI?\n2. What adverse medical events, if any, occur during the treatment with Huanjingjian decoction? To answer these questions, researchers will compare Huanjingjian decoction plus hormone replacement therapy (HRT) with placebo plus HRT, in order to determine whether Huanjingjian decoction provides additional therapeutic benefits in the management of POI.\n\nParticipants will:\n\nReceiving either Huanjingjian decoction plus HRT, or placebo plus HRT. Attending monthly clinic visits over a 6-month period for clinical assessments and laboratory testing.\n\nKeeping a detailed diary to record symptoms, treatment adherence, and menstrual flow, as measured by the number of sanitary pads used.",[631],"Premature Ovarian Insufficiency",[633,634,635,636],"premature ovarian insufficiency","menopause","traditional Chinese herbal formula","Huanjingjian decoction",{"date":638,"type":39},"2025-09-08",{"date":245,"type":22},{"date":641,"type":22},"2030-07-30",{"name":45,"class":46},""]